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A STUDY OF COMPARISON OF LEFT VENTRICULAR MASS IN 
HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS AND 
WITHOUT DIABETES MELLITUS 
ABSTARCT 
BACKROUND AND OBJECTIVES: 
                              Hypertension is a major risk factor for stroke, cardiovascular 
diseases and aortic dissection and hypertension is associated with significant 
morbidity and mortality. Hypertension causes 7.1 million premature deaths and 
the disease burden is 4.5% all over the world.  Hypertension is a major public 
health problem globally. The prevalence of diabetes has raised to 285 million in 
2012 when compared to 30 million cases in 1985.  The principal morbidity and 
driver of mortality in patients with diabetes are cardiovascular diseases (CVD). 
Both hypertension and diabetes increases cardiovascular morbidity and 
mortality by increasing left ventricular mass. .  Even though the ECG can 
identify the findings suggestive of left ventricular hypertrophy, the sensitivity is 
very less. So echocardiography is preferred for assessment of left ventricular 
hypertrophy.  
MATERIALS AND METHODS: 
    This was a prospective cross sectional study conducted in patients attending 
the hypertension OP of Govt. Kilpauk Medical College Hospital with 
hypertension and diabetes or hypertension alone of more than 5 years duration 
without any cardiac disease and healthy individuals of more than 35yrs of age 
are taken as controls. Echocardiography was done for both study and control 
groups and left ventricular mass was calculated by using Penn formula and LV 
mass was compared between the three groups (HT, HT and DM, controls). 
RESULTS: 
       There is significant statistical correlation between age group and left 
ventricular mass in hypertension with diabetes group (p =0.039). There is 
significant statistical correlation between females (p=0.042) with diabetes and 
hypertension and severity of abnormal left ventricular mass than males 
(p=0.286). The mean left ventricular mass increases in both males (211.25gm-
HT to 224.24gm-HT+DM) and females (169.65gm-HT to 206.06gm-HT+DM) 
in hypertension and diabetes group and it was statistically significant in females 
(p=0.015) but not in males (p=0.546). 
CONCLUSION: 
     The study shows that there is increased left ventricular mass in females with 
hypertension and diabetes mellitus when compared to females with 
hypertension alone but not in males. But the mean left ventricular mass was 
increased in both males and females of diabetes and hypertension group when 
compared to hypertension only group. Advancing age is also associated with 
increased left ventricular mass in cases of both hypertension and diabetes group. 
Increased left ventricular mass is an important cause for increased 
cardiovascular morbidity and mortality hence, the females with diabetes and 
hypertension should be managed aggressively for reduction of left ventricular 
mass.   
KEY WORDS: 
Left ventricular mass, Hypertension, Diabetes mellitus, Echocardiography, Penn 
formula, Cardiovascular diseases. 
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I. INTRODUCTION 
          Hypertension is a major risk factor for stroke, cardiovascular diseases and 
aortic dissection and hypertension is associated with significant morbidity and 
mortality. The WHO estimates that hypertension may cause 7.1 million 
premature deaths and the disease burden 0f 4.5% all over the world.  
Hypertension is a major public health problem globally. 
         The development of echocardiography has offered new approaches 
regarding the pathophysiology and clinical implications that affect the 
hypertensive patients. Echocardiography is very important in the clinical 
management of any hypertensive patient.  Even though the ECG can identify 
the findings suggestive of left ventricular hypertrophy, the sensitivity is very 
less. The sensitivity of the criteria using ECG for LVH was 7% to 35% in 
moderate hypertrophy and 10% to 50% in severe hypertrophy. So 
echocardiography is preferred for assessment of left ventricular hypertrophy. In 
echocardiography, M-mode technique is the gold standard test.  
          Diabetes mellitus refers to “A group of common metabolic disorders that 
share the phenotype of hyperglycemia. The metabolic dysregulation associated 
with DM causes secondary pathophysiologic changes in multiple organ systems 
that impose a tremendous burden on individuals with diabetes as well as on the 
health care system”. 
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          Diabetes mellitus also predisposes to cardiovascular diseases. In diabetes 
mellitus hyperinsulinemia (insulin resistance), high HbA1c and dysautonomia 
contributes to increased left ventricular mass. Compared to non-diabetic 
individuals, diabetic individuals have raised morbidity and mortality from 
cardiovascular disease. 
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II. REVIEW OF LITERATURE 
II. 1. HYPERTENSION: 
          Hypertension is a major public health problem all over the world. 
Approximately 7.6 million deaths (13-15% of the total) and 92 million disability 
adjusted life years worldwide were attributable to high blood pressure in 2001. 
Hypertension doubles the risk of cardiovascular diseases, including coronary 
heart disease, congestive heart failure, ischemic and hemorrhagic stroke, renal 
failure and peripheral arterial diseases. Because of increasing obesity and 
population aging, hypertension burden is increasing globally and projected to 
affect 1.5 billion persons (one third of world’s population) by the year 2025. By 
current data, hypertension causes 54% of stroke and 47% of ischemic heart 
disease throughout the world 
(74)
. Antihypertensive therapy reduces the risk of 
cardiovascular renal diseases. 
II. 1. a. Epidemiology: 
          Prevalence of hypertension, blood pressure levels and the rate of age-
related increases in blood pressure vary among countries and subpopulations 
within a country. Hypertension is less prevalent in individuals living in 
primitive and culturally isolated societies. In early adulthood the average 
systolic blood pressure was higher for men in the United States, whereas in ages 
60 and above it is higher for women when compared to men.  
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           There is a progressive increase in diastolic blood pressure upto 55 years 
after which it progressively decreases. As a result, beyond the age of 60, there is 
widening of pulse pressure. The probability of developing systemic 
hypertension is 90% for a middle aged or elderly person in his or her lifetime. 
II. 1. b. Definition: 
           Hypertension is defined as “Blood pressure of  140/90 mmhg” for 
which there are definitely established benefits from drug treatment which 
decreases morbidity and mortality 
(75)
. The criterion for defining hypertension 
was recommended by JNC 7. It has been classified as patients having normal 
blood pressure, prehypertension and stage 1, stage 2 hypertension.   
           15 to 20% of patients diagnosed as stage I hypertension based on office 
blood pressure have ambulatory reading less than 135/85mmhg.  This is called 
as white coat hypertension. It may also be associated with risk of target organ 
damage and risk of developing sustained hypertension.      
          Target organ damage is better predicted by home blood pressure 
including 24-hour blood pressure recording than do office blood pressures. 
After waking up, the early morning period blood pressure tends to be higher 
than that other times of day, which explains why myocardial infarction has 
more common in early morning hours. 
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           TABLE 1: Joint National Committee 7(Jnc7) Classification of     
                                Blood Pressure (BP)
 (102)
 
 
          There is 10 to 20% decrease in blood pressure during night-time when 
compared to day and when this doesn’t happen there is increased risk of 
cardiovascular diseases. 
II. 2. DIABETES MELLITUS 
II. 2. a. Definition: 
          “Diabetes mellitus is a group of diseases characterised by insufficient 
production of insulin or by the failure to respond appropriately to insulin, 
resulting in hyperglycemia”.  
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          For the past two decades, the prevalence of diabetes has raised more 
dramatically to 285 million in 2012 when compared to 30 million cases in 1985.  
           According to the current trends, the estimation by International Diabetes 
Federation states that, by the year 2030 diabetes prevalence may increases upto 
438 million. Compared to type 1, type 2 diabetes prevalence rises more rapidly 
which may be due to reduced physical activity, increasing obesity, 
industrialisation and it also increases with age of the individuals.  
           In the United States, the estimation of prevalence of diabetes during 2010 
showed that 11.3% in individuals with >20 years age group, 0.2% in individuals 
aged < 20years, 26.9% in individuals aged >65years. In men and women the 
prevalence is similar in most age groups (11.8% in men and 10.8% in women,   
in individuals aged >20years). According to the worldwide estimation, by 2030 
the diabetic individuals with age group 45-64 years will be more.  
           Eventhough much attention has been focused mainly on prevention and 
treatment of microvascular complications like nephropathy, neuropathy and 
retinopthy, the principal morbidity and driver of mortality in patients with 
diabetes are cardiovascular diseases (CVD) but also there is increased risk of 
cerebrovascular disease, heart failure and peripheral vascular diseases. 
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FPG – Fasting Plasma Glucose, 2-h PG – 2 Hour Plasma Glucose 
                 TABLE 2: Criteria for diagnosis of Diabetes mellitus 
II. 3. ANATOMY OF THE HEART 
           Most of the hollow organs of the body are made up of different types of 
muscular layers, but heart is entirely made up of a single muscle layer. In most 
hollow organs of the body muscle layers are composed of smooth and striated 
muscles but in the heart it is composed of specialised tissue cardiac muscle.  
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          All muscle types functions by contraction, causing the muscle cells to 
shorten. Skeletal muscle cell acts voluntarily after getting signals from brain. 
The smooth muscles which surround the hollow organ acts involuntarily; they 
do not need a signal from brain. Cardiac muscle also acts involuntarily. So, 
cardiac and smooth muscles are functionally similar. But cardiac and skeletal 
muscles are anatomically resembles more closely. Both cardiac and skeletal 
muscles are striated.  
          Cardiac muscles have several unique features. Three types of cardiac 
muscle are present, which includes atrial muscle, ventricular muscle, and 
specialised excitatory and conductive muscle fibres. Like skeletal muscle, 
cardiac muscle also has actin and myosin filaments. During contraction these 
filaments lie side by side and slide along one another. Cardiac muscle acts as a 
syncytium. They contain intercalated discs, which are cell membranes that 
separate the individual cardiac muscle cells from one another.  
           After slight stretching cardiac muscle contracts more powerfully. When 
the ventricles are filled, beyond their normal capacity they are stretched. This 
results in most powerful contraction of ventricles and hence maximum amount 
of blood forced into the arteries with each stroke. 
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                     FIGURE 1: Structure of the Cardiac Muscle 
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          The heart has four chambers, two atria and two ventricles. The atria 
receives blood from the veins which then contracts and pushes blood into the 
ventricle. Even if the atria fail to contract, most of the blood in atria will flow 
into the ventricle. Hence atria do not really have to work that hard. However the 
ventricles are the real work horses, since they must have sufficient power to 
push the blood away from the heart all the way to the last point of arterial tree. 
           The ventricular musculature is much thicker than the atrial musculature. 
The heart walls are made up of several spirally arranged muscle fibres, which 
push the blood from the ventricles during contraction. Heart valves present 
between the atria and ventricles allows unidirectional flow of blood.  
           The heart is composed of involuntary muscle which has self excitatory. 
Hence they can initiate contraction themselves. 
          Linzbach (1960)
1
 studied that for every myocardial fibre there is one 
capillary in a ratio of 1:1. In hypertrophied heart this remains same. Thus 
capillary inadequacy is not a cause of hypoxia in a hypertrophied heart. The 
ratio between coronary artery and coronary ostial diameter decreases in marked 
hypertrophy, which restricts myocardial perfusion in hypertrophied heart.  
           Spann et al (1969)
2
 had shown that in a non-failing hypertrophied heart, 
there is decrease in the development of tension and contraction in myocardial 
tissue which may ultimately leads to congestive cardiac failure later in due 
course of time. 
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           Grove et al (1969)
3
 showed that hyperplasia of myocardial cells occurs 
only in the embryonic and early postnatal growth.   
           Any subsequent myocardial enlargement in adult life can only be due to 
hypertrophy of the individual myocardial cells. 
           Benzak (1969)
4
 showed experimentally when cardiac workload returns to 
normal, myocardial cells returns to their original size. 
           Meerson (1969)
5
 had stated that compensatory hyper functioning of heart 
leading to hypertrophy occurs in response to abnormally increased workload. 
          Laks et al (1974)
6
 showed that an increase in cell length as a result of 
adding more sarcomeres cause cardiac hypertrophy rather than the result of 
stretching of sarcomeres. 
II. 3. a. Left ventricular hypertrophy: 
           Left ventricular hypertrophy is defined as “An abnormal increase in the 
mass of the left ventricle” which is an independent risk factor in predicting 
causes of cardiovascular morbidity and mortality like congestive heart failure, 
myocardial infarction and sudden cardiac death. 
          Pathologically LVH is defined as an “Increase in volume of cardiac 
myocytes”
7
. To normalise the wall stress, there occurs remodelling of the 
architecture of heart when there is hypertrophy of ventricles. The type of load 
imposed on the heart predicts the pattern of hypertrophy.  
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FIGURE 2: Pictorial Differentiation of Normal Heart and Left Ventricular 
Hypertrophy 
 
          Increased afterload causes an increase in systolic stress and also an 
increase in number of sarcomeres in parallel manner leading to increase in wall 
thickness with decrease in chamber size. It is termed as concentric hypertrophy
7
. 
It is seen in patients with pressure overload as in systemic hypertension. 
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          Increased preload causes an increase in diastolic stress which causes 
sarcomeres to be added in series leading to increase in chamber size. This 
increases ratio of chamber size to wall thickness and this type of ventricular 
hypertrophy is termed as eccentric hypertrophy
7
 which commonly occurs in 
case of volume overload of left ventricle like aortic regurgitation, mitral 
regurgitation. End stages of dilated cardiomyopathy are associated with 
eccentric hypertrophy. Clear distinction between concentric and eccentric 
hypertrophy can be made with a help of echocardiography. 
           In athletes, due to strenuous physical exercise, there occurs increased left 
ventricular mass with normal function. Pathological stress on the heart leading 
to left ventricular hypertrophy is associated with diverse consequences. 
 
II. 4. PHYSIOLOGY OF CARDIAC CONTRACTION 
II. 4. a. Myocardial Excitation Contraction coupling: 
 The myocardial tissue is made up of multiple fibres which in turn made 
up of multiple myofibrils. Each myofibril consists of subunits called as 
sarcomeres which are separated by horizontal lines called as Z lines which 
project into the sarcomeres and integrate with the thicker filament portion 
myosin. 
          Myosin acts as an adenosine triphosphatase by splitting adenosine 
triphosphate. Actin and myosin interacts and produces actomyosin which is a 
more potent ATPase when compared to myosin alone. 
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           Troponin and tropomyosin are the two other proteins which inhibit the 
contraction of actomyosin but when calcium ions binds to troponin and 
tropomyosin, these proteins are unable to inhibit actomyosin and contraction 
occurs. Thus, calcium ion is an inotropic factor.  
           There are two distinct channel systems on sarcolemma which are the ‘T’ 
system and sarcoplasmic reticulum which is a storage site for calcium ions.  
          There is a high intracellular concentration of potassium (K+) and low 
calcium (ca2+) and sodium (Na+) concentration in the sarcolemma during 
diastole which is maintained by cell membrane by an active process and is 
enzyme dependent. When depolarisation occurs there is rapid entry of sodium 
into the cells during the first phase of action potential. 
           During the second phase calcium ions enters slowly into the cells, which 
can be blocked by magnesium ions and drugs like verapamil and acidosis, 
opposite effect is exerted by methyxanthine and catecholamine which increases 
calcium content of myocardial cell producing an inotropic effect. There is a 
relationship between intracellular calcium and sodium concentration. When 
sodium is extruded out of the cell, for every three sodium ions one extracellular 
calcium ion enters into the cell resulting in increased intracellular concentration.  
II. 4. b. The Role Of Muscle Length: 
The force of contraction depends on the initial muscle length. The 
sarcomere length of 2.2micrometers is associated with most powerful 
contraction. The two sets of sarcomere myofilaments are ideally situated at this 
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length to provide the greater area for their interaction. The thin filaments are 
entirely withdrawn from the A band and no tension develops when the 
sarcomere length is increased to 3.65micrometers. The capacity of force 
development also declines when the sarcomere is shorter than 2micrometer. 
Since the thin filaments bypass one another and thereby producing a double 
overlap, which leads to cause a reduction in the sensitivity of contractile sites.  
           The basis of the Frank starlings reaction ( starlings law of heart ) which 
states that “Within limits the augmentation of initial volume of the ventricle, 
which is function of the initial length of the cardiac muscle, results in an 
increase in the force of the ventricular contraction”. 
II. 4. c. The Force Velocity Curve: 
          The mechanical activity of all muscle depends on shortening and 
development of tension. There is inverse relationship between the velocity of 
shortening and magnitude of tension development within the muscle. There is 
alteration in the contractile activity of the myocardium under physiological 
conditions by changes in the inotropic states and changes in the resting muscle 
fibre length which shift the myocardial force velocity curve. 
II. 4. d. Ventricular Wall Tension And The Laplace Relationship: 
 
           Afterload is the resistance against which the ventricles contract i.e., the 
arterial wall resistance, the peripheral vascular resistance, aortic impedance, the 
column of the blood mass in the aorta and the viscosity of the blood.  
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           Ventricular myocardial pressure is related to the intraventricular pressure 
per centimetre square of surface upon which the pressure is exerted.  
          At the beginning of ventricular ejection and the time of peak systolic 
pressure, the wall tension begins to decrease and less than that at the onset of 
systole. The stimulus for myocardial hypertrophy is believed to be this 
increased tension in dilated hearts.  
          There is increased ventricular performance several beats after aortic 
pressure raise is the additional influences of alteration in afterload. Some studies 
state that this phenomenon can be due to recovery from transient subendocardial 
ischemia which is caused by sudden alteration in arterial pressure. 
II. 4. e. Contractility And The Ionotropic State: 
          The change in the inotropic state (contractility) of the muscle which is 
independent of the change in afterload or preload (fibre length) alters the 
myocardial function is the third major mechanism. This indicates that when 
there is augmentation of contraction, at any given length for any given load the 
myocardium shortens faster and generates force. 
II. 4. f. Heart Rate (Bow Ditch Effect): 
           The heart rate or the frequency of cardiac contraction is the fourth major 
determinant of cardiac function. Because of this mechanism, during the periods 
of exercise or increased demand there is increased cardiac output. Increased 
contraction and relaxation also occurs due to increased heart rate which 
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improves diastolic performance. The TREPPE, STAIRCASE PHENOMENON 
or BOWDITCH EFFECT is the systemic force-interval relationship.            
The negative or reverse staircase phenomenon or WOODWORTH 
PHENOMENON is the “recuperative effect of a long pause” upon the strength 
of contraction. 
II. 4. g. Other Factors: 
           Atrial function, ventricular diastolic dysfunction, adequacy of ventricular 
contraction, hormonal control, nervous control etc., are the other factors that 
influence ventricular contraction. 
 
II. 5. LEFT VENTRICULAR HYPERTROPHY PATTERNS AND 
PATHOGENESIS: 
II. 5. a. Patterns of Left Ventricular Hypertrophy: 
One of the principles involved in the heart’s compensatory activity for 
increased load is the development of left ventricular hypertrophy. In both the 
volume and pressure loaded conditions, there is approximately equally 
increased left ventricular systolic stress, mass and diastolic pressure. In volume 
loaded ventricles, the wall thickness was increased substantially. The latter was 
just enough to counter balance the increased radius so that in volume 
overloaded conditions, there is normal wall thickness to radius ratio, while there 
was disproportionate thickening of ventricular wall. Thus the systolic stress is 
maintained relatively unchanged in compensated patients. The compensatory 
  
18 
 
mechanism for increased load is hypertrophy, which adversely causes slowing 
relaxation and increasing stiffness.  
 This stiffness can be due to  
1.  An increased intrinsic stiffness of myocardium (due to myocardial ischemia, 
fibrosis, amyloid infiltration). 
2.  Without alteration of intrinsic ventricular myocardial thickness, there is an 
increased ventricular wall thickness and mass. 
3.  Can be due to combination of these two mechanisms. 
II. 5. b. Morphology of cardiac hypertrophy: 
II. 5. b. i. Early stage:  
          In this stage, myofibrils and mitochondria will increase in number, which 
is followed by enlargement of mitochondria with nuclei and increasing length 
of muscle cells with preservation of cellular organisation. 
II. 5. b. ii. Advanced stage: 
          In this stage also the specific organelles size and numbers are increased. 
Along with this there is occurrence of subtle changes in cellular organisation 
due to localised cell areas have irregular addition of new contractile elements.  
II. 5. b. iii. Long standing Hypertrophy:  
           Here the nuclei are markedly enlarged and high lobulation of membranes 
with breakdown of normal Z- band registration. The cellular organisation is 
more obviously disrupted in this stage. 
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II. 5. b. iv. Late stage of hypertrophy: 
          There is marked disruption of Z bands with loss of contractile elements.  
The changes include: 
Ø Severe disruption of the parallel arrangement of sarcomere  
Ø Fibrous tissue deposition 
Ø T-tubules showed dilatation and increased tortuosity. 
II. 5. c. Chronic mechanical overload of Heart and changes in membrane    
proteins: 
          Mechanical origin of cardiac hypertrophy causes alteration of number 
and density of membrane proteins in an equivocal way. There are two distinct 
groups of protein distinguished. 
Ø The calcium
2+
-ATPase of the sarcoplasmic reticulum, the low affinity 
isoform of the Na
+
k
+
ATPase and beta one adrenergic and muscarinic 
receptors form one group of membrane proteins. Because of hypertrophic 
process not involved in activation of protein synthesis in this group, their 
changes in number per cell do not occur. The adaptive slowing down of 
relaxation is reflected by the decreasing density of ca
++
ATPase of the 
sarcoplasmic reticulum, whereas the beta receptors down regulation have 
some protective role.  
Ø The calcium channels and also by one isoform of Na
+
k
+
ATPase forms 
another group of membrane proteins. Because of this group of proteins 
activated proportionately by the degree of hypertrophy, their number per cell 
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increases. The chronic mechanical overload induces the gene coding for 
these proteins. 
          In volume overloaded conditions, activation of matrix metallo-
proteineases (gelatinase, collagenase and stromalysins) 
(79, 80, 81) 
produces tissue 
inhibitors down-regulation and thereby causing chamber expansion by changing 
collagen matrix. 
II. 5. d. Hemodynamic Stimuli In The Development Of Left Ventricular 
Hypertrophy 
(89)
: 
          Arterial vasoconstrictors like angiotensin II and norepinephrine  
increases arterial stiffness. This increases pulse pressure which in turn further 
increases systolic blood pressure. Chronic high blood presssure leads on to 
produce left ventricular hypertrophy and thereby increases left ventricular mass. 
This increased LV mass produces remodelling effect on left ventricle and 
produces diastolic dysfunction.  
          Other factors like atherosclerosis also increases LV mass by the same 
way like hypertension. . In obesity, increased metabolic rate increases stroke 
volume  which in turn produces volume overloaded hypertrophic changes on 
heart which is called as ecccentric hypertrophy. 
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LV- Left ventricle, LVH – Left ventricular hypertrophy, NL- Normal, 
LVM- Left ventricular mass, RWT- Regional wall thickness 
Figure 3: Hemodynamic Stimuli In The Development Of Left Ventricular 
Hypertrophy
 (89)
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II. 6. ETIOPATHOGENESIS OF LEFT VENTRICULAR 
HYPERTROPHY IN HYPERTENSION: 
            
           The preferential synthesis of mitochondria is the first cellular change that 
occurs after the stimulus for hypertrophy, presumably the sufficient adenosine 
triphosphate provided by expanded myocardial mass which helps to meet the 
energy demands of the hypertrophied cell. Then the myofibril mass will 
increase later. This can taken place only when there is depression of the DNA in 
the nucleus of myocytes, which allows DNA replication to occur. 
The stimuli for left ventricular hypertrophy includes 
Ø ATP depletion. 
Ø Because of sustained increase in preload and afterload there is stretching 
of myocytes do occurs (sympathetic nervous system). 
Ø Due to wear and tear mechanism there is accumulation of products of cell 
degeneration occurs. 
Ø Humoral factors for stimuli include rennin-angiotensin, thyroid 
hormones, growth hormones, epinephrine, etc. 
          L.H Missault et al (2002) 
(60)
 studies the relationship between left 
ventricular mass and blood pressure. There is a higher correlation when systolic 
blood pressure or night-time blood pressure is considered. In conclusion the 
relationship between blood pressure and left ventricular mass is low once the 
hypertension is treated. It is found that night-time blood pressure dippers have 
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better prognosis than non-dippers and hence night-time blood pressure better 
correlates with left ventricular mass than day-time blood pressure 
(61)
.  
          Hond et al (2003) 
(63)
 studied the relationship between systolic blood 
pressure and left ventricular mass using baseline left ventricular mass and 
different types of blood pressure like 24-hour ambulatory blood pressure, day-
time blood pressure, office-blood pressure and night-time blood pressure. There 
is a strong association of echocardiographic mean wall thickness with 
ambulatory blood pressure than with office blood pressure. 
II 6 a. Sympathetic Nervous System Influence On Myocardial 
Hypertrophy: 
          Sympathetic innervation of the heart mediates the increased heart rate     
and myocardial contractility due to pressure and volume loaded conditions. 
Norepinephrine is described as a myocardial hypertrophy hormone by laks
6
. 
Through alpha receptors norepinephrine stimulates the growth of isolated 
cultured myocardial cells as shown by Samson. Diuretics stimulates 
sympathetic nervous system despite causing marked decrease in blood pressure, 
diuretics did not lead to regression of cardiac hypertrophy. This explains the 
failure of diuretic therapy produces reversal of hypertrophy. 
         Administration of methyldopa leads to decrease in norepinephrine in 
circulation, which leads to reduction of left ventricular mass without reduction 
in blood pressure.   
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FIGURE 4: Sympathetic Nervous System Influence On LVH 
           A solid arrow represents the excitatory neural influences and inhibitory 
neural influences on sympathetic outflow of heart, kidneys and peripheral 
vasculature are represented by dotted arrows. AII –Angiotensin II, EPI –
epinephrine, NE – Norepinephrine, NTS – Nucleus tractus solitarius, Ach – 
Acetylcholine. 
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          Whereas treatment with alpha blockers (clonidine) leads to reduction of 
left ventricular mass and associated decrease in blood pressure 
          Similarly beta adrenergic antagonists also cause reduction of left 
ventricular hypertrophy. However after 12 months of treatment with beta 
blockers (metoprolol) J. Wikman- coffelt et al
8
 demonstrated very protracted 
regression of left ventricular hypertrophy. 
II. 6. b. Genetic Determination Of Myocardial Hypertrophy: 
          In 14% of hypertensive patients, there is asymmetrical septal 
hypertrophy. 
This may be due to the following reasons: 
Ø Ventricular septum hypertrophies earlier in response to increased systemic 
pressure load even before the hypertrophy of anterior or posterior wall on 
account of its longer radius of curvature.  
Ø The concentration of catecholamines is higher in ventricular septum which 
account for the higher prevalence of septal hypertrophy on hypertension. 
    Since essential hypertension is genetically determined, the response of 
heart to hypertrophy is also being genetically determined. There occurs an 
individually varying genetic component in all cases of hypertensive cardiac 
hypertrophy. This explains the fact that response to antihypertensive treatment 
varies in different patients. 
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II. 6. c. Endothelial Cell Dysfunction: 
   The relaxing factors such as prostacyclin (PGI2), nitric oxide (NO) and  
endothelium derived hyperpolarizing factors are released when specific 
receptors (organ circles) on endothelial membrane by blood and platelet derived 
substances. Contracting factors like angiotensin II, endothelin I, prostaglandin 
H2 (PGH2), and thromboxane A2 (TXA2) are also released from the 
endothelial membrane. 
           The major defence against hypertension is constituted by the endothelial 
lining of blood vessels which is an important factor which determines the 
vascular health. Dysfunctional endothelium is characterised by an imbalance 
between endothelium derived contracting and relaxing factors, which causes 
increased release of endothelium derived constricting, prothrombotic, 
proinflammatory and growth factors like transforming growth factor beta 
(TGF– , thromboxane and endothelin. There is decreased release of 
endothelium derived relaxing factors like endothelium derived hyperpolarizing 
factor and nitric oxide.  
            Francesco et al (1999) 
(65, 66)
 showed that both endothelial dysfunction 
and left ventricular hypertrophy forms the background for the development of 
hypertension. This study showed that there is a inverse relationship between 
endothelium dependent vasodilating agent acetylcholine and echocardiographic 
left ventricular mass in hypertensive patients. 
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FIGURE 5: Endothelium Derived Relaxing And Constricting Factors
 (104)
 
 
         The activation of specific receptors (orange circles ) on the endothelial 
membrane by various blood and platelet-derived substances causes release of 
relaxing factors like prostacyclin (PGI2), nitric oxide (NO) and endothelium –
derived hyperpolarizing factor (EDHF). There is also release of contracting 
factors like endothelin (ET-1), thromboxane A2 (TXA2), angiotensin (AII) as 
well as    prostaglandin H2 (PGH2), 5-HT – serotonin, ACE - angiotensin-
converting enzyme,  Bk- bradykinin, L-Arg - l-arginine, ECE - endothelin-
converting enzyme, NOS - nitric oxide synthase, TGFβ1- Transforming growth 
factor- β1,  O2− = superoxide, Thr – Thrombin. . 
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II. 6. d. Vascular Remodelling:  
         Overtime elevated blood pressure, neurohormonal activation and 
endothelial dysfunction causes remodelling of blood vessels 
(95,96)
. In small and 
large arteries the hallmark of hypertensive remodelling is an increase in the 
media thickness compared to lumen diameter (ratio of media-lumen is 
increased).  
         Vasoconstriction is the initial effect of remodelling in the small arteries, 
which normalises wall stress and thereby averts the trophic response. A smaller 
lumen diameter was surrounded by rearrangement of normal smooth muscle 
cells; this process is called as inward eutrophic remodelling. Without alteration 
of medial cross sectional area, there is increase in media to lumen ratio.  
         The hemodynamic hallmark of diastolic hypertension is “In the peripheral 
circulation, by decreasing lumen diameter systemic vascular resistance is 
increased by inward eutrophic remodelling”. 
         In large arteries the remodelling process is characterised by, triggering 
expression of hypertrophic genes which in turn increases medial thickness and 
media to lumen ratio.  
         This hypertrophic remodelling is characterised by increased in size of 
vascular smooth muscle cells and also extracellular matrix proteins such as 
collagen and fibronectin accumulation which is caused by TGF-   activation. 
This in turn produces stiffness of large arteries which is the hemodynamic 
hallmark of isolated systolic hypertension.  
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FIGURE 6: Vascular Remodelling Of Small And Large Arteries In 
Hypertension 
(103)
 
   
Tunica media, tunica adventitia, tunica intermedia are showed in this diagram 
by cross section of arteries. 
II. 6. e. Hormonal Mechanisms Involved In Hypertension:  
II. 6. e. i. Renin-Angiotensin Aldosterone System: 
          The one of the most important mechanism which involved in endothelial 
cell dysfunction is the renin – angiotensin – aldosterone system. Because of 
activation of this mechanism vascular remodelling and hypertension occurs.  
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AI – Angiotensin I, AII- Angiotensin II, ACE – Angiotensin converting 
enzyme, AT1R – Angiotensin 1Receptor.         
FIGURE 7: Renin-Angiotensin Systen Activation In HT 
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  Renin is a protease, secreted by renal juxtaglomerular cells, which cleaves the 
angiotensinogen to angiotensin I, this further produces angiotensin II by 
angiotensin converting enzyme.      
        Angiotensin converting enzyme is most abundantly present in the lungs 
and also in the systemic vasculature and (tissue ACE) and heart. The alternative 
pathway for conversion of angiotensin II from angiotensin I is by a serine 
protease chymase which is present in the heart and systemic arteries. The 
numerous cellular processes that are involved in hypertension and its end organ 
damage is produced by the interaction between G- protein coupled angiotensin 
I receptors and angiotensin II. The cellular processes involved in hypertension 
includes vasoconstriction, vascular inflammation, generation of reactive oxygen 
species, the production of aldosterone, the principal mineralocorticoid and 
vascular and cardiac remodelling.  
           There is increasing evidence that the damage of vascular health thereby 
causing hypertension is due to activation of multiple signalling pathways by 
angiotensin II, aldosterone and even renin and prorenin.    
II. 6. e. ii. Effect of Renin-Angiotensin system on left ventricular 
hypertrophy: 
           During treatment with angiotensin converting enzyme inhibitors there is 
regression of left ventricular hypertrophy. This shows that angiotensin II has a 
strong role in causing left ventricular hypertrophy 
(97, 98)
. Angiotensin II 
stimulates biosynthesis of myocardial protein has been reported by sahn et al
9
. 
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Through angiotensin 1 receptor, angiotensin II induces molecular events and 
thereby producing hypertrophy 
(82, 83, 84, 85, 86). 
           Sympathetic tone is enhanced by angiotensin by its central and peripheral 
action on autonomic nervous system and thereby stimulates the adrenal medulla 
to secrete catecholamines.    
          Secondarily this tropic action of angiotensin II is mediated by 
catecholamines. This is proved by the fact that special angiotensin analogues 
which do not release catecholamines have no effect on myocardial hypertrophy. 
II. 6. e. iii. Receptor mediated actions of Angiotensin II: 
          There are two types of angiotensin receptors. Angiotensin I receptor is 
widely present in the kidney, heart, liver, adrenals, vasculature and brain.  Most 
of the hypertensive actions of angiotensin II occur due to the activation of 
Angiotensin I Receptor 
(100, 101)
. The angiotensin I receptor activation leads on 
to produce vasoconstriction, cell growth and proliferation, aldosterone release, 
activation of sympathetic system, and inhibition of renin release which further  
produces cardiac hypertrophy. 
        The activation of angiotensin II receptor produces opposite actions of 
angiotensin I and thereby inhibits cardiac muscle hypertrophy.  
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 FIGURE 8: Opposite Actions Of Angiotensin II Receptors (AT1, AT2) 
(99)
 
PAI-1 – Plasminogen Activator Inhibitor-1; NO- nitric oxide; PGI2- 
Prostaglandin I 2 (Prostacyclin); 
 
The enhanced angiotensin I receptor mediated signalling pathway,  explains the 
mechanism for coexisting occurrence of high blood pressure with 
atherosclerosis and insulin resistance and this constitutes the therapeutic target 
for attenuating the progression of cardiovascular disease from vascular 
remodelling by formation of atherosclerotic plaque to myocardial infarction 
(MI), stroke and death.  
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AII – Angiotensin II, MI – Myocardial infarction, NE – Norepinephrine. 
FIGURE 9: Cardiovascular Disease Progression By Angiotensin Receptor 1 
Mediated (AT1 R) Signalling  
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II. 6. f. Reduced Coronary Reserve In Systemic Hypertension And Blood        
Rheology: 
           Hgn poiseuille law describes the relation between blood pressure, blood 
flow and blood viscosity. There is direct relationship between the blood flow to 
radius of the vessel and pressure gradient and inverse relationship between 
vessel length and blood viscosity. 
The mechanisms involved in increase of plasma viscosity by arterial 
hypertension include: 
Ø Because of transcapillary shift of fluid into interstitial space due to 
hydrostatic pressure there is reduction of intravascular volume. 
Ø Due to activated interleukins, there is synthesis of fibrinogen degradation 
products in the precapillary vessels which increases synthesis of 
fibrinogen and other acute phase proteins from liver. 
So the occurrence of arterial hypertension such as left ventricular hypertrophy 
and coronary vascular reserve reduction due to the following mechanisms: 
Ø Inadequacy of vascular capacity. 
Ø Secondary to medial hypertrophy, there is reduction of arteriolar 
diameter. 
Ø The distensability of  the pre-capillary resistance vessels has been 
reduced. 
Ø Increased vasomotor tone like some functional alterations occurs. 
Ø Blood fluidity has been impaired.                
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II. 7. INFLUENCE OF DIABETES MELLITUS ON LEFT 
VENTRICULAR MASS: 
II. 7. a. Pathophysiologic changes Diabetes Mellitus: 
          Type 2 Diabetes Mellitus is characterised by insulin secretion 
impairment, insulin resistance, increased hepatic glucose production and fat 
metabolism abnormalities. The common factor in type 2 diabetes is obesity, 
particularly visceral or central which is evidenced by hip-waist ratio (  80% are 
obese). Despite insulin resistance, the glucose tolerance remains normal in early 
stages of the disease, which is due to the development of compensatory 
mechanism of beta cells by increasing insulin output.  
          In certain individuals, the pancreatic islets are unable to sustain the 
hyperinsulinemic state due to the progression of insulin resistance and 
compensatory hyperinsulinemia. Following elevations of postprandial glucose, 
Impaired Glucose Tolerance (IGT) develops. A further decreased insulin 
secretion and increased production of hepatic glucose lead on to overt diabetes 
mellitus with high fasting blood sugar. Finally beta cell failure occurs.  
II. 7. b. Background of left ventricular hypertrophy in diabetes:  
           Left ventricular hypertrophy is a frequent finding in diabetic individuals. 
It defines the powerful marker of poor prognosis of cardiovascular diseases 
including Americans and Africans. This left ventricular structure alteration not 
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only related to diabetes but also related to hypertension, central obesity, obesity, 
aging, salt intake, dyslipidemia and physical inactivity.  Among these 
hyperglycemia or hyperinsulinemia per se largely associated with left 
ventricular structural abnormalities. Individuals with type 2 diabetes mellitus 
echocardiographic left ventricular hypertrophy are usually associated with 
susceptibility to increased albuminuria
10
 and atherothrombosis
11
, which is a 
marker of endothelial dysfunction and microangiopathy
12
. This explains the 
pathologic link between inflammation and left ventricular hypertrophy.      
II. 7. c. Mechanisms involved in increased left ventricular mass in Diabetes 
Mellitus: 
           The changes in gene expression, endothelial function, myocytes growth, 
myocardial substrate utilisation and myocardial compliance in the heart are due 
to alteration of downstream transcription factors which is induced by 
hyperglycemia, increased reactive oxygen species (ROS) and hyperlipidemia. 
II. 7. c. i. Hyperglycemia: 
           The excess production of advanced glycation end-products (AGEs) is the 
principal abnormality which deactivates nitric oxide (NO) and impairs coronary 
vasodilatation. Prolonged hyperglycemia causes increased formation of 
mitochondrial reactive oxygen species (ROS)
 13
, which produces the following 
effects on the heart. 
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Reactive Oxygen Species (ROS)               
 
Decreases nitric oxide levels                                               Affects transcription
14 
 
 
Myocardial inflammation and endothelial dysfunction     contractile dysfunction 
          This advanced glycogen end-products related reactive oxygen species 
formation
 (15) 
also produces deposition of collagen in the myocardium and then 
myocardial fibrosis 
(16,17)
. Metallothionein is a potent antioxidant which helps to 
prevent the formation of left ventricular hypertrophy 
(18)
 thereby increased left 
ventricular mass. 
           Hyperglycemia itself can promotes the left ventricular hypertrophy with 
involvement of transforming growth factor beta 1by synthesis of collagen by 
cardiac fibroblasts through the phosphatidylinositol 3- kinase and protein kinase 
C (PKC)
(19)
 beta pathways.  
II. 7. c. ii. Effect of Insulin on left ventricular hypertrophy: 
         Insulin acts as a growth hormone for cardiac myocytes through the protein 
kinase C (PKC) and/or extracellular signal regulated kinase (ERK) pathways. 
PARP [poly (ADP-
ribose) polymerase 
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                       Insulin also interacts with the neurohormonal system  
                          Activates the sympathetic nervous system 
(20) 
                        Increases the pressor response to angiotensin II 
Increases the stimulating effects of angiotensin II on extracellular signal      
regulated kinase (ERK) pathways
 (21)
 
Cellular proliferation and extracellular matrix deposition 
II. 7. c. iii. Fatty acids in Diabetes and Left ventricular mass: 
          Increased fatty acids in diabetes individuals and also increased 
dependence of diabetic myocardium on fatty acids produce several major 
cellular perturbances. So there is increased beta oxidation and accumulation of 
long -chain acyl carnitines in the mitochondria producing uncoupling of 
oxidative phosphorylation 
(22)
. Inhibition of pyruvate dehydrogenase by 
enhanced fatty oxidation produces decreased glucose and pyruvate utilisation. 
This pyruvate oxidation is activated by Peroxisome-proliferator-activated 
receptor (PPAR) 
(23)
.  The net result is an excess production of glycolytic 
intermediates and also increased ceramide synthesis which leads on to 
apoptosis. PPAR-  and -  agonist prevents this apoptosis 
(23)
.  Thus impaired 
pyruvate oxidation, glycolysis and lactate uptake and also a fatty acid 
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dependence as a source of acetyl CoA can lead on to a perturbation of  
myocardial  bioenergetics and contraction – relaxation coupling
 (24)
. 
II. 7. c. iv. Renin – Angiotensin System influence in Diabetic Left 
Ventricular Hypertrophy: 
           In diabetes individuals, even minimal changes in myocardial loading up-
regulates the renin-angiotensin system 
(25)
. Insulin-like growth factor-1 (IGF-1) 
down-regulates the p53 DNA binding and thereby causes reduction in the 
transcription of angiotensinogen and also reduces angiotensin II levels results in 
reduction of cardiomyocyte apoptosis 
(26)
. So insulin like growth factor-1 gene 
over expression down regulates the renin-angiotensin system and thereby 
inhibits the development of left ventricular hypertrophy
 (27, 28)
. Cardiac 
hypertrophy produced by chronic activation of renin angiotensin activation 
system.  This RAAS system in turn produces cellular alterations by angiotensin 
II and thereby producing cardiac hypertrophy 
(90, 91, 92, 93, 94)
.  
II. 7. c. v. Aldosterone induced increased left ventricular mass:  
           Aldosterone and angiotensin II can increases LV mass by excessive 
accumulation of collagen and enhanced fibroblast proliferation in vivo 
(29,30,31,32)
.  
In a dose dependant manner aldosterone and angiotensin II also enhance the 
human cardiac fibroblast to synthesize collagen in vitro 
(33, 34)
.  
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          In a diabetic patient, because of alterations in the microvasculature, 
diffuse fibrosis has been noticed throughout the myocardium. Analysis of 
cardiac tissue in a diabetic patients showed that there is accumulation of 
collagen in interstitial and focal perivascular area which indicates the fibrosis 
(35)
. In a diabetic patient, hyperglycemias dysregulates renin-angiotensin -
aldosterone system thereby produces cardiac fibrosis through stimulation of 
myofibroblast growth, which is mediated by aldosterone and glucose 
(36, 37)
.  
II. 7. c. vi. Vascular Endothelial Growth Factor (VEGF):  
           The expression of mRNA and protein for VEGF and its receptors such as 
VEGF-R1 and VEGF-R2 has been reduced significantly (40%-70%) in a 
diabetic patients
 (38)
. Because of this the normal molecular process which 
regulates the angiogenesis has been impaired 
(39)
.  
II. 7. c. vii. Gene Expression:  
           Increased expression of genes such as contractile proteins - Myosin 
heavy chain ( -MHC), -skeletal actin and atrial light chain 1 in left ventricular 
hypertrophy and cardiac failure in some studies 
(40, 41)
.  
II. 7. c. viii. Endothelial Dysfunction: 
           Diabetes is associated with anatomical and functional abnormalities of 
vascular endothelium 
(42)
. Endothelial dysfunction in chronic hyperglycemia 
contributes to impaired endothelial nitric oxide (NO) production 
(43)
, enhanced 
production of vasoconstrictor prostaglandins, endothelium adhesion molecules, 
vascular and platelet growth factors and glycated proteins which cumulatively 
  
42 
 
increases the vasomotor tone and vascular permeability and thereby enhances 
growth and remodelling.  
           The other features of endothelial dysfunction includes the weakening of 
intercellular junctions, protein synthesis alteration, accelerated disappearance of 
capillary endothelium 
(44)
, adhesion glycoproteins production/expression. These 
alterations on endothelial cells promote the attachment of monocytes and 
leucocytes. Also transendothelial migration occurs. This chronic hyperglycemia 
induced endothelial dysfunction also enhances endothelial cell matrix 
production which further contributes to basement membrane thickening 
(45)
. 
Endothelial dysfunction can also enhance atherosclerosis in diabetic individuals. 
II. 8. ECHOCARDIOGRAPHY AND LV MASS: 
          Echo sounding was first applied in 1920 by humans for recording of 
depth in oceanographic studies and submarine detection. By definition 
“Ultrasound is the sound having a frequency of greater than 
20000cycles/second”. Ultrasonography device uses a piezoelectric transducer. 
Use of pulse reflected ultrasound for non destructive testing was first used by 
firestone. 
          The use of ultrasonography for examination of heart was first done by 
Keidal. Dr. Hertz initiated the use of pulse reflected ultrasonography. A number 
of ultrasonic studies of heart were done by Elder. Feigenbaum H. Popp R.L 
(46)
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and associates (1968) used ultrasonic methods for measuring left ventricular 
wall thickness. 
          Measurement of left ventricular wall thickness and mass by 
echocardiography was first published by Troy, Rackley and Pombo in 1972 
(47)
. 
Murray J.A Johnston W, Reid J.W et al showed good results by correlating left 
ventricular volume and dimension by echocardiography with angiographic 
studies 
(48)
. 
          Devereux. R (1976) using penn convention method calculated the left 
ventricular mass by echocardiography and they used angiographic studies
 (49) 
for 
calculation of left ventricular mass. 
           The echocardiography instrumentation has been complex with evolution 
from M mode to 2-Dimensional echocardiography. Also from 2D-
echocardiography to doppler techniques with colour coding. 
           A 12-lead electrocardiography is readily available diagnostic modality 
for left ventricular hypertrophy which is commonly used by many physicians 
for detection of left ventricular hypertrophy 
(50)
. Sensitivity of 
electrocardiography for detecting left ventricular hypertrophy is 49% and 
specificity of 95% by casale’s modified electrocardiographic criteria. This limits 
the use of electrocardiography for detecting left ventricular hypertrophy and 
hence increases the need for other diagnostic tools 
(51)
. The presence of left 
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ventricular hypertrophy can be accurately assessed by echocardiography which 
is difficult to be detected by electrocardiography 
(52)
. 
          Daniel savage et al 
(53)
 showed that echocardiography identified left 
ventricular hypertrophy in 50% of hypertensive patients, whereas 
electrocardiography identified less than 10% cases. Echocardiography is a 
reliable and reproducible method for measuring left ventricular mass and left 
ventricular wall thickness as shown by Bart L. Troy 
(54)
. In hypertensive patients 
the diagnostic method of choice for measuring left ventricular hypertrophy is 
echocardiography 
(55)
. M mode echocardiography used for evaluation of left 
ventricular hypertrophy gives information about both wall thickness and cavity 
size. 
           Pearson et al 
(7)
 found that M mode echocardiography has sensitivity of 
88% and specificity of 84% for detecting left ventricular mass which is better 
than 2-Dimensional echocardiography. 
           In Framingham study 
(56)
, it is showed that echocardiography has a high 
sensitivity in predicting risk stratification in left ventricular hypertrophy when 
compared to electrocardiography. Donna et al (2003) 
(62)
 found that for 
estimating quantitative measurement of left ventricular mass uses 
echocardiographic chamber dimension and left ventricular wall thickness 
measurements. While echocardiographic M mode left ventricular images are 
measured using strip-chart paper tracings and hand-held callipers, in digitized 
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M-mode left ventricular images direct measurements were made on computer 
screens using electronic calipers.   
II. 9. LEFT VENTRICULAR MASS AND CARDIOVASCULAR 
MORBIDITY: 
          Casale et al 
(57)
 studied cardiovascular risks of left ventricular 
hypertrophy. In this study men with left ventricular hypertrophy had a higher 
risk of cardiovascular morbidity than men without left ventricular hypertrophy 
of same age, blood pressure and cholesterol levels (24% vs. p<0.01).  
           Koren MJ et al 
(87)
 and Verdecchia P et al 
(88)
 explained that intermediate 
risk of target organ damage occurs with eccentric hypertrophy (normal relative 
wall thickness and increased left ventricular mass) and highest risk of target 
organ damage occurs with concentric hypertrophy (increased relative wall 
thickness and left ventricular mass). 
           There is higher incidence of atherothrombotic brain infarctions and new 
cardiac events in patients with echocardiographic evidence of left ventricular 
hypertrophy. There occurs more frequent episodes of complex ventricular 
ectopics in patients with left ventricular hypertrophy than without left 
ventricular hypertrophy. Levy et al 
(56,58,59) 
 in their Framingham study of 6218 
patients showed that complex ventricular arrhythmias occurs in patients with 
echocardiographic evidence of left ventricular hypertrophy. There is a six-fold 
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increase in coronary mortality and eight-fold increase in cardiovascular 
mortality in patients with left ventricular hypertrophy 
(56)
 
           Adewole et al (2006) 
(64)
 showed that left ventricular hypertrophy is an 
independent risk factor for cardiovascular events. It is shown that combination 
of relative wall thickness and left ventricular mass identified different forms of 
left ventricular geometry. The prognosis is worst with concentric hypertrophy.  
                      Paolo verdecchia et al (2001) 
(67)
 showed that in uncomplicated 
patients with essential hypertension, echocardiographic demonstration of left 
ventricular mass as a prognostic value and they found a strong relation between 
left ventricular mass and cardiovascular morbidity. 
           Systolic and diastolic function abnormalities occur due to increased left 
ventricular mass 
(69, 70, 71)
. The thickness of left ventricle shown by 2-
Dimensional echocardiography correlates with left ventricular mass. Normal 
thickness ranges from 0.6 to 1.1 centimetres and when the thickness is >1.1cm 
there is associated left ventricular hypertrophy. 
          High blood pressure may account for 37% of total cardiovascular diseases 
in men and 27% in women, 30% of myocardial infarction in women and 14% in 
men, 59% of chronic heart failure in women and 39% in men, 35% of ischemic 
strokes and 56% of chronic kidney diseases.  
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           Randomised controlled trials have proved that reducing blood pressure 
with antihypertensive treatment reduces total mortality of coronary heart 
diseases, heart failure, stroke and chronic kidney diseases. 
           Okin et al (2007) 
(68)
 showed that with antihypertensive therapy  there is 
regression of electrocardiographic left ventricular hypertrophy and it is 
associated with decreased incidence of atrial fibrillation. 
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III. AIM OF THE STUDY 
Ø To compare the left ventricular mass in hypertensive patients with 
diabetes mellitus and without diabetes mellitus. 
Ø To compare these two groups with controls. 
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IV. BACKGROUND 
IV. 1. Selection of subjects: 
      Patients with hypertension alone and patients with both   hypertension  
and diabetes mellitus of more than 35 years attending the hypertension 
outpatient department of kilpauk medical college hospital. The selected patients 
should be on regular treatment not on cardiac remodelling drugs like 
angiotensin converting enzyme inhibitors and aldosterone antagonists. Control 
groups with more than 35 years without diabetes mellitus and  
hypertension.  
IV. 2. Inclusion Criteria:  
Ø All patients > 35 yrs of age with hypertension of duration > 5yrs on 
regular treatment. 
Ø Patients >35yrs of age with hypertension and diabetes mellitus >5yrs 
duration on regular treatment.  
Ø Healthy controls of >35yrs of age. 
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IV. 3. EXCLUSION CRITERIA:  
Ø Coronary Artery Disease 
Ø Valvular Heart Disease 
Ø Chronic Kidney Disease of non diabetic origin 
Ø Obesity 
Ø Cardiomyopathies    
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V. MATERIALS AND METHODS: 
 
Setting:  Kilpauk Medical College. 
Study design:  Prospective Cross sectional study 
Period of study:  6 months from March 2013 to August 2013. 
Sample size:  150 subjects (50 Hypertensive cases + 50 Cases of both 
hypertension and diabetes + 50 controls). 
V. 1. Both cases and controls are investigated by following measures: 
Ø Proper history and past medical history and demographic details were 
collected. 
Ø General examination , Vitals monitoring includes blood pressure and 
pulse rate 
Ø  Body Mass Index 
Ø Fasting and Post Prandial Blood Sugar  
Ø Complete hemogram 
Ø Blood Urea, Serum Creatinine and Serum Electrolytes Urine analysis 
Ø Serum Total Cholesterol, Serum Triglyceride levels. 
Ø Electrocardiography 
Ø Chest X-Ray 
Ø 2-Dimensional Echocardiography 
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V. 2. Echocardiography:  
By using transthoracic 2-Dimensional echocardiographic method,  
the following left ventricular dimensions are measured by M-mode technique 
using the parasternal long axis view just above/at the tip of the papillary muscle 
level. 
Ø Left ventricular internal diameter at end diastole (LVID-D) 
Ø Interventricular septal thickness at end diastole (IVST-D) 
Ø Posterior wall thickness at end diastole (PWT-D) 
 
FIGURE 10: Two dimensional guided M mode echocardiogram of left 
ventricle at papillary muscle level 
(73)
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Apart from this measurements, left systolic functions, diastolic 
functions and ejection fractions also measured. 
           Left ventricular mass was calculated by penn convention method which 
was first used by Devereux and colleagues during 1981. They found that this 
formula best correlates with anatomic left ventricular mass. 
LV mass = 1.04[(LVID-D+IVST-D+PWT-D)
 3
 – (LVID-D)
 3
]-13.6gm. 
 
TABLE 3: Reference values of left ventricular mass 
(72)
: 
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V. 3. Statistical Analysis:  
           Mean values of all parameters in groups were calculated by independent 
sample t-test. To compare the distributions of dichotomous data viz., age, 
gender, body mass index, smoking, alcoholism, duration of hypertension and 
diabetes mellitus and left ventricular mass, Chi-square test was used.  ANOVA 
test was used for comparing mean LV mass in between three groups.  
Association of LV mass between hypertension group and group of both 
hypertension and diabetes mellitus was assessed by logistic regression model. 
          All statistical analysis were performed using SPSS (Software Package 
used for Statistical Analysis) package. A p- value of less than 0.05 was 
considered to be statistically significant. 
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VI. OBSERVATION ANALYSIS: 
Table 1: Age wise distribution of cases (hypertensive groups and groups of 
both hypertension and diabetes) and controls: 
   Group 
    Control HT 
HT + 
DM 
Age in 
years 
36-45 Count 
13 8 7 
    % within 
Group 
26.0% 16.0% 14.0% 
  46-55 Count 28 16 12 
    % within 
Group 
56.0% 32.0% 24.0% 
  Above 55 Count 9 26 31 
    % within 
Group 
18.0% 52.0% 62.0% 
 
           The minimum age of the cases and controls was 36 years and maximum 
age was 85 years. Among 50 hypertensive cases 16% were in 36-45yrs, 32% 
were in 46-55yrs, 52% were in above 55yrs with mean age of 58.06 yrs. 
Likewise among 50 cases with both hypertension and diabetes mellitus, there 
were 14%, 24% and 62% with mean age of 58.44yrs and among 50 controls 
there were 26%, 56% and 18% with mean age of 49 yrs in each of the above age 
groups respectively.  
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Chart 1: Age wise distribution of cases (hypertensive groups and groups of 
both hypertension and diabetes) and controls: 
 
 
 
Table: 2: Age wise distribution of left ventricular mass in three groups: 
Group   Age in years 
 
 
p value 
  36-45 46-55 Above 55  
     
    0.248 
Control LV mass Normal 13 27 8 
    Mild 0 0 1 
    Moderate 0 1 0 
HT LV mass Normal 5 9 9  
    0.543     Mild 0 3 6 
    Moderate 0 1 2 
    Severe 3 3 9 
HT +DM LV mass Normal 5 4 4  
    
    0.039 
    Mild 0 2 5 
    Moderate 0 2 2 
    
 
Severe 
2 4 20 
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From the above table (Table:2), there is significant statistical correlation 
between left ventricular mass and age group in cases with both hypertension and 
diabetes group with the p value of 0.039.The left ventricular mass increases 
with age in this group. But in control group and cases with hypertension only 
group, the p value was 0.248 and 0.543 respectively and it was not statistically 
significant. 
Chart 2: Age wise distribution of left ventricular mass in three groups: 
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Table 3: Sex wise distribution of cases in of cases (Hypertensive groups and 
groups of both Hypertension and Diabetes) and controls: 
   Group 
    Control HT HT + DM 
Sex Male Count 21 23 22 
    % within 
Group 
42.0% 46.0% 44.0% 
  Female Count 29 27 28 
    % within 
Group 
58.0% 54.0% 56.0% 
             
           Among 50 cases with hypertension, 23 were male and 27 were female, 
i.e., 46% and 54% respectively. Likewise, among 50 cases with both 
hypertension and diabetes mellitus 22(44%) were male and 28(56%) were 
females. Among controls 21(42%) were male and 29(58%) were females. 
Chart 3: Sex wise distribution of cases in three groups:
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Table 4: Sex wise distribution of left ventricular mass in three groups: 
         
          Among 23 male cases with hypertension normal left ventricular mass 
were 12(52.2%), mildly abnormal were 4(17.4%), moderately abnormal were 
0(0%), severely abnormal were 7(30.4%). Likewise among 22 male cases with 
hypertension and diabetes, normal were 8(36.4%), mild, moderate and severely 
abnormal were 4(18.2%), 3(13.6%), 7(31.8%) respectively. Among 21 male 
controls 20(95.2%) were normal, 1(4.8%) were mildly abnormal. 
           Among 27 female cases with hypertension normal were 11(40.7%), mild, 
moderate and severely abnormal were 5(18.5%), 3(11.1%), 8(29.6%) 
respectively. Among 28 female cases with hypertension and diabetes 5(17.9%) 
were normal, mild, moderate and severely abnormal were 3(10.7%), 1(3.6%), 
Sex   Group  
 
p value   
 
Control HT HT+DM 
Male LV 
mass 
 
Normal 
           
             20 
 
               
12 
 
             8 
 
 
 
  0.286     Mild 1 4 4 
    Moderate 0 0 3 
    Severe 0 7 7 
Female LV 
mass 
 
Normal 
 
28 
 
11 
 
5 
 
 
  0.042     Mild 0 5 3 
    Moderate 1 3 1 
    Severe 0 8 19 
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19(67.9%) respectively.   Among 29 female controls 28 were normal and 1 was 
moderately abnormal.  
          From the above table (Table: 4), female gender has significant correlation 
with severity of LV mass (p = 0.042). The following bar diagram (Chart: 4) 
explains that there is increased LV mass in females with both hypertension and 
diabetes groups when compared to other two groups. But there is no significant 
statistical correlation between male gender and left ventricular mass (p = 0.286).  
Chart 4: Sex wise distribution of left ventricular mass in three groups:
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Table 5: BMI wise distribution of cases and controls in three groups:
 
   Group 
    Control HT HT + DM 
BMI Normal Count 31 27 24 
    % within 
Group 
62.0% 54.0% 48.0% 
  Overweight Count 19 23 26 
    % within 
Group 
38.0% 46.0% 52.0% 
 
           Among 50 cases with hypertension 27 were having normal BMI, 23 were 
having overweight. Likewise cases with both hypertension and diabetes 24 were 
normal BMI, 26 were having overweight. Among 50 controls 31 were normal 
BMI, 19 were overweight.  
Chart 5: BMI wise distribution of cases and controls: 
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Table 6: BMI wise distribution of left ventricular mass in three groups: 
Group   BMI  
p value   Normal Overweight 
Control LV mass Normal 30 18  
 
0.325 
    Mild 1 0 
    Moderate 0 1 
    Severe 0 0 
HT LV mass Normal 14 9  
 
0.084 
    Mild 2 7 
    Moderate 3 0 
    Severe 8 7 
HT+ DM LV mass Normal 7 6  
 
0.624 
    Mild 3 4 
    Moderate 3 1 
    Severe 11 15 
     
          Among cases with hypertension with abnormal BMI, 7(30.4%) had 
severely abnormal left ventricular mass. In the same way cases with 
hypertension and diabetes with abnormal BMI, 15(57.7%) had severely 
abnormal left ventricular mass.  Likewise controls, only 0% have abnormal or 
severely left ventricular mass.  
          From the above table (Table: 6) compared to hypertensive cases, cases 
with hypertension and diabetes group have more percentage of cases having 
severe  left ventricular mass increases with increase in BMI, but this is not 
significant statistically (p > 0.05).  
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Chart: 6: BMI wise distribution of LV mass in three groups: 
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Among 50 cases with hypertension, 4 (8%) were have more than 15 years 
duration of hypertension. Likewise cases with both hypertension and diabetes 
6(12%) have more than 15 years duration of hypertension and diabetes. 
Chart 7: Distribution of cases according to the duration of HT/HT+DM: 
 
Table 8: Distribution of LV mass according to the duration of HT/HT+DM: 
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    Among 50 cases with hypertension 4(8%) have >15yrs duration of 
hypertension and all these cases had normal LV mass. Likewise among cases 
with hypertension and diabetes 6(12%) have >15yrs duration, within this 2 
(33.3%) have severely abnormal left ventricular mass. There is no significant 
statistical correlation between duration of HT/DM and LV mass in two groups 
(p>0.05).   
Chart 8: Distribution of LV mass according to the duration of HT/HT+DM: 
 
Table: 9: Mean LV mass according to the duration of HT in HT only group: 
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The mean LV mass in hypertension only group was nearly same in various 
durations of hypertension. 
Table: 10: Mean LV mass according to the duration of HT/DM in Both HT and 
DM group: 
 
LV mass 
Mean SD Minimum Maximum 
Duration of 
HT/DM 
6-10 214.52 66.05 88.47 379.37 
11-15 204.29 62.82 102.48 296.70 
Above 15 229.42 68.84 152.47 330.65 
 
The mean LV mass was increasing from 214.52gm to 229.42gm with increase 
in the duration of HT and DM in the group with both hypertension and diabetes. 
Table 11: Distribution of DD among three groups: 
   Group 
    Control HT HT + DM 
DD No DD Count 44 20 16 
    % within 
Group 
88% 40.0% 32.0% 
  Grade1DD Count 6 30 34 
    % within 
Group 
12% 60.0% 68.0% 
     
           Among 50 hypertensives 30(60%) had grade 1DD, likewise 34(68%) had 
grade 1 DD in cases with both hypertension and diabetes. Among controls 
6(12%) having grade 1 DD. There is significant statistical correlation (p=0.001) 
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between DD and cases with hypertension with diabetes group compared to 
others.                             
Chart 9: Distribution of DD among three groups: 
 
Table 12: Correlation DD and LV mass among three groups: 
Group   DD  
p value 
  No DD Grade 1 DD 
Control LV mass Normal 44 4  
 
0.001 
    Mild 0 1 
    Moderate 0 1 
  severe 0 0 
HT LV mass Normal 9 14  
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           From the above table (Table:12) 15 cases with hypertension and diabetes 
group had severely abnormal left ventricular mass  9 cases had grade 1 DD, 
likewise cases with both hypertension and diabetes group, 26 of severely 
abnormal left ventricular mass 19 have grade 1DD. So there is significantly 
increased number of cases with hypertension and diabetes group with increased 
left ventricular mass have diastolic dysfunction. But there is no statistical 
correlation between DD and LV mass in groups (HT, HT+DM) with p value of 
> 0.05. 
Chart 10: Correlation DD and LV mass among three groups: 
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Table 13: Distribution of smoking among three groups: 
   Group 
    Control HT HT + DM 
Smoking Yes Count 6 9 6 
    % within 
Group 
12.0% 18.0% 12.0% 
  No Count 44 41 44 
    % within 
Group 
88.0% 82.0% 88.0% 
          Among hypertensive groups 9(18%), likewise in groups of both 
hypertension and diabetes 6(12%), and in controls 6(12%) were having history 
of smoking. 
Chart 11: Distribution of smoking among three groups:
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Table 14: Correlation of smoking and LV mass among three groups: 
    
Control HT HT+DM 
Smoking Yes LV mass Normal 6 6 3 
   
Mild 0 2 0 
   
Moderate 0 0 1 
   
Severe 0 1 2 
 
No LV mass Normal 42 17 10 
   
Mild 1 7 7 
   
Moderate 1 3 3 
   
Severe 0 14 24 
      
Among 9 smokers in hypertensive groups, 1 have severely abnormal LV mass, 
likewise among 6 smokers of both hypertensive and diabetics group 2 have 
severely abnormal LV mass. There is no statistical correlation (p>0.05) between 
smoking and LV mass.  
Chart 12: Correlation of smoking and LV mass among three groups: 
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Table 15: Distribution of Alcoholism among three groups:
   Group 
    Control HT HT + DM 
Alcoholism Yes Count 6 9 7 
    % within Group 12% 18.0% 14.0% 
  No Count 44 41 43 
    % within Group 88% 82.0% 86.0% 
       
          Among the 22 of alcoholics, 9(40.9%) were in hypertensive group, 7 
(31.8%) were in both hypertensive and diabetics group and 6 were in control 
group.  
Chart 13: Distribution of Alcoholism among three groups: 
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Table 16: Correlation of Alcoholism and LV mass among three groups:
    
Control HT HT+DM 
Alcoholism Yes LV mass Normal 6 7 6 
   
Mild 0 1 0 
   
Moderate 0 0 1 
   
Severe 0 1 0 
 
No LV mass Normal 42 16 7 
   
Mild 1 8 7 
   
Moderate 1 3 3 
   
Severe 0 14 26 
           Among 9 alcoholics of hypertensive cases 1 have severely abnormal LV 
mass, likewise among 7 alcoholics of both hypertensive diabetics group only 1 
have moderately abnormal LV mass, none have severely abnormal LV mass. 
There is no statistical significance (p>0.05) between LV mass and alcoholism. 
Chart 14: Correlation of Alcoholism and LV mass among three groups: 
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Table 17: Comparison of LV mass between three groups (HT, HT+DM):  
  
          Among hypertensive groups 27(54%) have abnormally increased LV 
mass, likewise in hypertensive diabetic groups 37(74%) have abnormal LV 
mass compared to 2(4%) in control groups. 
 
 
 
  
Group 
Total    Controls HT 
HT+DM 
LV 
mass 
  
      
Normal Count 48 23 13 84 
   % within LV 
mass 
57.1% 27.4% 15.5% 100.0% 
   % within 
Group 
96.0% 46.0% 26.0% 56.0% 
   
Mild 
Count 1 9 7 17 
   % within LV 
mass 
5.9% 52.9% 41.2% 100.0% 
   % within 
Group 
2.0% 18.0% 14.0% 11.3% 
   
Moderate 
Count 1 3 4 8 
   % within LV 
mass 
12.5% 37.5% 50.0% 100.0% 
  % within Group 2.0% 6.0% 8.0% 5.3% 
   
Severe 
Count 0 15 26 41 
   % within LV 
mass 
.0% 36.6% 63.4% 100.0% 
   % within group      
.0% 
.0% 30% 52%  27.3% 
Total Count 50 50 50 150 
  % within LV 
mass 
33.3% 33.3% 33.3% 100.0% 
  % within Group 100.0% 100.0% 100.0% 100.0% 
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Table 18: Statistical comparison (Chi- Square Test) of LV mass in three 
groups: 
 Value Df p value 
Pearson Chi-Square 56.009(a) 6 .000 
Likelihood Ratio 
68.787 6 .000 
Linear-by-Linear 
Association 
47.189 1 .000 
N of Valid Cases 150     
      
 p value is 0.001, so there is significant statistical correlation of LV mass 
between these three groups. 
Chart 15: Comparison of LV mass between three groups                              
(HT, HT+DM, Controls): 
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Table 19: Comparison of LV mass between two groups (HT, HT+DM): 
   Group Total 
    HT HT + DM   
LV 
mass 
Normal Count 
23 13 36 
    % within LV mass 63.9% 36.1% 100.0% 
    % within Group 46.0% 26.0% 36.0% 
  Mild Count 9 7 16 
    % within LV mass 56.3% 43.8% 100.0% 
    % within Group 18.0% 14.0% 16.0% 
  Moderate Count 3 4 7 
    % within LV mass 42.9% 57.1% 100.0% 
    % within Group 6.0% 8.0% 7.0% 
  Severe Count 15 26 41 
    % within LV mass 36.6% 63.4% 100.0% 
    % within Group 30.0% 52.0% 41.0% 
Total Count 50 50 100 
  % within LV mass 50.0% 50.0% 100.0% 
  % within Group 100.0% 100.0% 100.0% 
 
          While comparing these two groups (HT, HT+DM) according to the 
severity of LV mass, the difference of LV mass was not statistically significant 
(p = 0.106). So we did subgroup analysis between male and female cases 
separately in these groups. 
 
  
 
  
76 
 
Table 20: Comparison LV mass between two groups (HT, HT+DM) in relation 
with Gender: 
 
          The table 20&21 explains that there is significant statistical correlation 
(p=0.042) of LV mass between female hypertensive and both hypertensive 
diabetic group. 
        But there is no significant statistical correlation in males of HT and DM 
group (p = 0.286). 
 
Sex     Group 
    HT HT + DM 
Male LV 
mass 
Normal Count 
12 8 
      % within Group 52.2% 36.4% 
    Mild Count 4 4 
      % within Group 17.4% 18.2% 
    Moderate Count 0 3 
      % within Group .0% 13.6% 
    Severe Count 7 7 
  
 
    % within Group 
30.4% 31.8% 
Female LV 
mass 
Normal Count 
11 5 
      % within Group 40.7% 17.9% 
    Mild Count 5 3 
      % within Group 18.5% 10.7% 
    Moderate Count 3 1 
      % within Group 11.1% 3.6% 
    Severe Count 8 19 
      % within Group 29.6% 67.9% 
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Table 21: Chi-Square test for Comparison LV mass between two groups (HT, 
HT+DM) in relation with Gender: 
Sex   Value Df  p value 
Male Pearson Chi-Square 3.780(a) 3 .286 
  Likelihood Ratio 4.942 3 .176 
  Linear-by-Linear 
Association 
.673 1 .412 
  N of Valid Cases 45     
Female Pearson Chi-Square 8.216(b) 3 .042 
  Likelihood Ratio 8.454 3 .038 
  Linear-by-Linear 
Association 
6.521 1 .011 
  N of Valid Cases 55     
 
Table 22: Comparing the mean LV mass in between two groups  
(HT, HT+DM): 
  Group N Mean Std. Deviation Std. Error Mean 
LV mass HT 50 188.7868 62.57260 8.84910 
  HT + DM 50 214.0584 64.71982 9.15276 
 
     
          After comparing mean left ventricular mass between these two (HT, 
HT+DM) groups, this gives p value of 0.050 and not statistically significant. 
But mean LV mass is increasing in HT+DM group. 
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Table 23: Chi-Square Test for Comparison the mean LV mass in between two 
groups (HT, HT+DM): 
   
Levene's 
Test for 
Equality 
of 
Variance
s t-test for Equality of Means 
    F 
Sig
. T Df 
p 
valu
e 
Mean 
Diffe
rence 
Std. 
Error 
Diffe
rence 
95% 
Confidence 
Interval of the 
Difference 
                  Lower Upper 
LV 
mass 
Equal 
variance
s 
assumed 
.014 
.90
8 
-
1.98
5 
98 .050 
-
25.27
16 
12.73
105 
-
50.535
96 
-
.0072
4 
  Equal 
variance
s not 
assumed 
    
-
1.98
5 
97.
88
9 
.050 
-
25.27
16 
12.73
105 
-
50.536
32 
-
.0068
8 
        
Table 24: Comparison of mean LV mass for males in between two groups (HT, 
HT+DM) (T-Test): 
  Group N Mean Std. Deviation 
Std. Error 
Mean 
LV mass HT 
23 211.2470 72.98173 15.21774 
  H T+ DM 22 224.2382 70.07182 14.93936 
 
 
          After that subgroup analysis done between these two groups (HT, 
HT+DM) according to the gender which showed that the mean left ventricular 
mass for males in hypertension group was 211.25gm and in hypertension and 
diabetics group was 224.24gm with p value of 0.0546. This explains that mean 
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left ventricular mass was increasing in the second group (HT+DM) but there is 
no significant statistical correlation in males of these groups (HT, HT+DM) and 
LV mass. 
Table 25: Chi-Square Test for Comparison of mean LV mass for males in 
between two groups (HT, HT+DM): 
   
Levene's 
Test for 
Equality 
of 
Variances t-test for Equality of Means 
    F Sig. T Df 
p 
valu
e 
Mean 
Diffe
rence 
Std. 
Error 
Differenc
e 
95% 
Confidence 
Interval of the 
Difference 
                  
Lowe
r Upper 
L
V 
ma
ss 
Equal 
variance
s 
assumed 
.155 .696 
-
.609 
43 .546 
-
12.99
12 
21.34493 
-
56.03
738 
30.05
493 
  Equal 
variance
s not 
assumed 
    
-
.609 
42.
99
9 
.546 
-
12.99
12 
21.32520 
-
55.99
762 
30.01
517 
 
 
Table 26: Comparison of mean LV mass for females in between two groups 
(HT, HT+DM) (T-Test): 
 
  Group N Mean Std. Deviation 
Std. Error 
Mean 
LV mass HT 27 169.6541 45.22834 8.70420 
  HT + DM 28 206.0600 60.26539 11.38909 
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Table 27: Chi-Square Test for Comparison of mean LV mass for females in 
between two groups (HT, HT+DM): 
   
Levene'
s Test 
for 
Equalit
y of 
Varianc
es t-test for Equality of Means 
    F 
Sig
. T Df 
p 
valu
e 
Mean 
Diffe
rence 
Std. 
Error 
Diffe
rence 
95% 
Confidence 
Interval of the 
Difference 
                  Lower Upper 
LV 
mas
s 
Equal 
variances 
assumed 
2.6
82 
.10
7 
-
2.52
7 
53 .015 
-
36.40
59 
14.40
876 
-
65.306
23 
-
7.505
62 
  Equal 
variances 
not 
assumed 
    
-
2.54
0 
50.
02
8 
.014 
-
36.40
59 
14.33
438 
-
65.196
97 
-
7.614
88 
 
 
          For females mean left ventricular mass for hypertension group was 
169.65 and for hypertension and diabetic group was 206.06 with p value of 
0.015. This explains that there is significant statistical correlation between 
females of these two groups (HT, HT+DM) and LV mass.    
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VII. DISCUSSION  
       In our study, we studied 150 subjects (50-HT only, 50- HT+DM, 50-
Controlswithout HT and DM) and they were compared with LV mass. The 
minimum age of the cases and controls was 36 years and maximum age was 85 
years. There is significant statistical correlation between age group and left 
ventricular mass in hypertension with diabetes group with the p value of 0.039. 
But in control group and cases with hypertension only group, the p value was > 
0.05 and it was not statistically significant. 
        There is significant statistical correlation between female (p=0.042) cases 
with diabetes and hypertension and severity of abnormal left ventricular mass, 
than males (p=0.286).   
      There is no significant statistical correlation between body mass index, 
diastolic dysfunction, smoking and alcoholism with left ventricular mass.   
       There is no significant statistical correlation between duration of 
hypertension and diabetes with LV mass (P>0.05) But there is increase in mean 
LV mass in hypertension and diabetes group. 
       While comparing LV mass between these three groups (HT, HT+DM, 
Control) there is significant statistical correlation (p =0.001) between three 
groups. But while comparing the two groups (HT, HT+DM), the difference of 
LV mass according to the severity of abnormal LV mass was not statistically 
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significant. So we did subgroup analysis between male and female cases 
separately in these groups. There is significant statistical correlation (p=0.042) 
of LV mass between hypertensive and both hypertensive and diabetic group 
females. But there is no significant statistical correlation of LV mass in males in 
these two groups.  
          Then we took mean LV mass and compared between the two (HT, 
HT+DM) groups. 
          While comparing mean left ventricular mass between these two (HT, 
HT+DM) groups, there is no significant statistical correlation (p=0.05) between 
LV mass and these groups.  
          After that subgroup analysis done between these two groups (HT, 
HT+DM) according to the gender which showed that the mean left ventricular 
mass for males in hypertension group was 211.25gm and in hypertension and 
diabetics group it was 224.24gm. This explains that mean left ventricular mass 
was increasing in the second group (HT+DM) but not correlated statistically 
(p=0.546). 
          For females mean left ventricular mass for hypertension group was 
169.65 and for hypertension and diabetic group was 206.06. This explains that 
there is significant statistical (p=0.015) correlation of increased LV mass in 
diabetes and hypertension group.  
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           In The Framingham study 
(20)
, they studied 2623 diabetic subjects out of 
which 1514 were women with mean age of 53 years without cardiac disease and 
they found that women more left ventricular mass compared to men with p 
value of < 0.001 for women and p=0.054 for men. They explained that the 
increased activation of serine/threonine protein kinase which is an inhibitor of 
apoptosis and also the oestrogen receptors in cardiomyocytes in females are the 
responsibility of increased LV mass in females.  
          Maurizio Galderisi 
(78) 
 and colleagues studied  2529 women and 1986 
men with diabetes and without cardiac disease, which shows that increased left 
ventricular mass in diabetic women with a p value of <0.05. 
           Alexander Tenenbaum and their colleagues
 (76)
 studied 550 hypertensive 
(314 men, 246 women), 200 of them (108 men, 92 women) was type 2 diabetes 
mellitus.  They found that female with diabetes and hypertension has higher 
prevalence of increased left ventricular mass compared to males. 
          The Augsburg family study 
(77)
 showed that increased left ventricular 
mass in female diabetics. 
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VIII. CONCLUSION 
     The study shows that there is increased left ventricular mass in  
females with hypertension and diabetes mellitus when compared to females 
with hypertension alone.    
      There is no significant difference in the left ventricular mass in males in 
between the two (HT, HT+DM) groups. 
     But the mean left ventricular mass was increased in both males and females 
of diabetes and hypertension group when compared to hypertension only group.  
     The increased duration of hypertension and diabetes is associated with 
increased mean left ventricular mass in cases of both hypertension and diabetes 
group. 
     In our study, advancing age group is associated with increased left 
ventricular mass in cases of both hypertension and diabetes group.  
     Hence, increased left ventricular mass is the important cause for increased 
cardiovascular morbidity and mortality, the females with diabetes and 
hypertension should be managed aggressively for reduction of left ventricular 
mass.  
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LIMITATIONS OF THE STUDY 
1. Study population is small. 
2. As echocardiography has observer variation, the same results need not be   
obtained in other similar studies. 
3. The duration of undiagnosed diabetes mellitus and hypertension in the       
patient who presented towards and taken into the study is not taken into 
consideration.  
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IX. b. PROFORMA: 
NAME:       
AGE:   
SEX: 
ADDRESS:       OP No: 
       
HISTORY AND PAST HISTORY: 
H/O Hypertension: 
H/O Diabetes Mellitus: 
H/O Coronary Artery Disease: 
H/O Valvular Heart Disease: 
H/O Chronic Kidney Disease: 
Drug History:  
GENERAL EXAMINATION: 
 Built:    Pallor:   Icterus: 
 Pedal oedema:             Temp:                 Hydration: 
 Clubbing:   PR:                BP:                         BMI: 
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Cardiovascular System: 
Respiratory System: 
Abdomen: 
Central Nervous System: 
Investigations: 
Blood: 
      Complete Hemogram: 
       Hb:            TC:            DC: P:      L:       M:      E:            ESR: 
       FBS: 
       PPBS: 
       B.Urea: 
       S.Creatinine: 
      Serum electrolytes:  Na:                K+: 
      Total Cholesterol: 
      Triglyceride level: 
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Urine:  
     Sugar: 
     Albumin:  
     Deposits: 
ECG: 
Echocardiography: 
LVIDD: 
PWTD: 
IVSTD: 
EF: 
Valves: 
Others: 
LV mass (penn) =1.04[(LVIDD+IVST-D+PWT-D)
 3
 – (LVIDD)
 3
] – 13.6gm. 
 
Chest X-Ray PA view 
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IX. c. ABBREVATIONS: 
HT     - Hypertension 
DM    - Diabetes mellitus 
LV mass – Left ventricular mass 
LVIDD   - Left ventricular internal diameter in diastole 
IVST- D – Interventricular septal thickness in diastole 
PWT- D – Posterior wall thickness in diastole 
2-D Echo – Two dimensional echocardiography 
ECG - Electrocardiography  
AT1- Angiotensin receptor 1 
AT II – Angiotensin receptor II 
RAAS – Renin-Angiotensin Aldosterone System 
PA view – Postero Anterior view 
RWT- Regional Wall Thickness 
EF – Ejection Fraction 
PR – Pulse Rate 
BP – Blood Pressure 
BMI – Body Mass Index 
DD – Diastolic Dysfunction 
FBS – Fasting Blood Sugar  
PPBS – Post Prandial Blood Sugar 
PPAR – Peroxisome Proliferated Activated Receptor 
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ERK – Extracellular singal Regulated Kinase pathways 
PKC – Phosphokinase C  
VEGF – Vascular Endothelial Growth  Factor 
IGF – Insulin-like Growth Factor 
MHC – Myosin Heavy Chain 
NO – Nitric Oxide 
ROS – Reactive Oxygen Species 
AGEs – Advanced Glycated End products 
IGT – Impaired Glucose Tolerance  
MI – Myocardial Infarction 
NE – Nor Epinephrine 
ACE – Angiotensin Converting Enzyme 
JNC – Joint National Committee 
  

MASTER CHART FOR HYPERTENSION WITHOUT DIABETES MEELITUS GROUP:   
 
Sl.No Name HT op no Age Sex Religion BMI 
HT 
duration Smoking Alcoholism BP LVID IVST PWT LV mass EF DD 
1 Chinnaiah 1325887 72 Male Hindu 23.88 6 Yes No 140/90 3.95 1.53 1.06 213.22 60 1 
2 Gopalakrishnan 2334/11 42 Male Hindu 24.61 6 No No 130/90 4.38 1.44 1.2 258.8 64 No 
3 Ramadoss 1184/12 73 Male Hindu 23.18 7 No No 140/90 5 1.4 1.1 295.15 74 1 
4 Rukmani 913/05 57 Female Hindu 24.34 11 No No 130/80 4.67 1.1 0.8 175.42 65 No 
5 Muthaiah 1326/13 70 Male Hindu 23.23 6 Yes Yes 140/90 4.23 1.12 0.9 161.59 60 No 
6 kaliammal 971/09 60 Female Hindu 23.53 6 No No 130/80 3.9 1.73 1.3 270.83 60 1 
7 Indrani 689/08 60 Female Hindu 24.84 17 No No 110/80 3.6 1.1 0.8 110.91 74 No 
8 Balaraman 32/10 68 Male Hindu 24.98 7 No No 130/80 4.9 1.53 1.37 357.58 64 No 
9 Rajamani 2245/06 50 Male Hindu 27.34 7 No No 140/80 4.2 1.1 1 169.4 65 No 
10 Perumal 1315/10 70 Male Hindu 23.14 8 No No 140/90 4.9 1.7 1 320.58 65 1 
11 Jayaraman 2030/10 60 Male Hindu 25.91 12 Yes Yes 140/90 3.87 1.66 1.32 260.4 72 No 
12 koneri 654/05 85 Male Hindu 27.34 12 No No 140/90 3.65 2.08 1.44 319.17 78 1 
13 Pandian 331/08 58 Male Hindu 23.88 20 No Yes 130/90 3.02 1.4 0.93 117.01 70 1 
14 Umarani 216/08 50 Female Christian 23.05 8 No No 140/90 4.7 1.35 1.01 244.4 76 1 
15 Moorthy 234/05 42 Male Hindu 22.49 8 No No 140/80 4.3 0.8 0.8 117.31 65 1 
16 Doss 6853/07 70 Male Christian 23.53 7 No No 140/90 4 1.5 0.7 167.7 80 1 
17 Raman 507/08 75 Male Hindu 25.71 6 No No 140/80 5.24 1.13 0.73 208.99 60 1 
18 Usha 2305/06 54 Female Hindu 24.97 7 No No 130/80 3.5 1.18 0.7 103.76 65 1 
19 Dinesh 2431/08 43 Male Hindu 25.39 6 Yes Yes 140/90 4.76 1.04 0.64 152.01 69 No 
20 Lakshmi 316/08 70 Female Hindu 28 6 No No 130/80 4.9 1.31 0.73 211.67 60 1 
21 Manonmani 717/11 65 Female Hindu 26.84 6 No No 130/90 4.3 1 0.9 151.57 78 1 
22 Selvi 421/03 41 Female Hindu 25.78 11 No No 130/90 3.1 1.02 1.1 103.34 66 No 
23 Sivagami 1784/09 45 Female Hindu 22.83 6 No No 140/90 3.97 1.1 0.9 142.61 72 1 
24 Amir 574/03 60 Male Muslim 28.13 11 Yes Yes 140/90 5.2 1.1 0.8 212.4 72 1 
25 Somasundaram 838/08 42 Male Hindu 24.98 6 No No 130/90 4.53 2.2 0.8 333.76 65 1 
   
26 Krishnamoorthi 1954/13 52 Male Hindu 24.22 7 Yes Yes 140/90 4.6 1.1 0.6 145.22 70 No 
27 Harikrishnan 195/12 55 Male Hindu 24.68 6 No Yes 140/90 4.96 0.95 0.7 159.85 60 1 
28 Gowri 99/07 55 Female Hindu 11 11 No Yes 140/90 4.68 0.95 0.75 149.88 60 1 
29 Abdhul Wahib 1700/10 67 Male Muslim 24.98 6 Yes No 130/90 4.62 1.16 0.92 196.64 70 1 
30 Lakshmi 251/12 45 Female Hindu 24.97 6 No No 130/80 4.3 1.25 0.96 190.64 60 1 
31 Vasu 412/12 50 Male Hindu 24.91 6 Yes No 140/80 4.96 0.87 0.58 133.4 65 1 
32 Babu 501/09 63 Male Hindu 25.71 6 Yes Yes 140/70 5.15 0.87 0.63 150.19 67 1 
33 Pamana 150/10 47 Female Hindu 28.89 6 No No 120/80 5.04 1.06 0.58 163.26 67 1 
34 Chandra 1493/07 50 Female Hindu 28.67 6 No No `130/80 4.58 1.06 0.67 147.77 67 1 
35 Shajahan 193/09 50 Male Muslim 25.71 6 No No 130/80 4.78 1.3 0.9 226.49 69 1 
36 Fazudein 324/05 73 Male Muslim 25.91 16 No No 140/90 5.2 1 0.7 181.82 73 1 
37 Malliga 1136/13 50 Female Hindu 27.53 20 No No 130/80 4.3 0.96 0.86 142.1 65 No 
38 Mehroon 2177/05 52 Female Muslim 26.04 8 No No 120/80 4.2 1 0.8 133.99 63 1 
39 Vennila 261/09 70 Female Hindu 27.64 8 No No 130/80 3.8 1.1 0.9 132.25 60 No 
40 Rajamani 477/05 74 Female Hindu 27.34 8 No No 120/80 4.7 1.1 0.7 164.03 65 No 
41 Rosy 496/10 60 Female Christian 27.24 6 No No 120/80 4.5 1 0.8 151.68 65 1 
42 Muniammal 1529/13 50 Female Hindu 25.48 6 No No 130/80 4.8 1.3 0.9 228.1 68 No 
43 Thangamani 296/01 75 Female Hindu 25.39 8 No No 130/80 5.1 1.1 0.8 205.16 70 1 
44 Sakunthala 193/12 59 Female Hindu 24.01 6 No No 140/90 3.9 1.2 0.9 149.35 65 1 
45 Mysiammal 480/06 50 Female Hindu 24.03 7 No No 140/80 4.5 1.1 0.9 177.24 67 No 
46 Ansar Bee 1856/06 50 Female Muslim 25.56 8 No No 130/70 4.7 1.3 0.9 220.07 70 No 
47 Valsala 1166/07 39 Female Hindu 23.53 6 No No 110/80 4 1 0.8 122.76 65 No 
48 Regina 2947/07 47 Female Christian 22.55 6 No No 120/80 3.9 1.3 0.9 160.77 65 No 
49 Lakshmi 366/12 65 Female Hindu 26.67 6 No No 140/70 4.4 1.7 0.9 254.53 70 No 
50 Kanagavalli 2027/13 73 Female Hindu 23.53 6 No No 130/80 3.9 1.4 0.9 172.57 68 No 
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1 Kannan 1366/02 70 Male Hindu 24.98 6 6 No No 130/90 110 150 5.1 1.5 1.3 361.2 60 No 
2 Radhakrishnan 1325942 58 Male Hindu 24.8 16 16 Yes No 130/80 120 165 5.28 1.36 1.18 330.65 63 1 
3 Mariammal 1325635 60 Female Hindu 26.04 16 16 No No 140/90 130 190 4.79 1.07 0.6 152.47 60 1 
4 Kanniyammal 1326847 65 Female Hindu 28.25 7 8 No No 140/90 128 198 3.9 1.63 1.38 267.85 65 1 
5 Meena 1326969 40 Female Hindu 23.83 9 8 No No 130/90 108 156 5.2 1.75 0.8 324.27 60 1 
6 Samuvel 719/02 81 Male Christian 25.21 6 7 No No 130/90 120 200 5.02 1.78 1.16 379.37 70 No 
7 Nagapushpam 647/10 57 Female Hindu 24.13 8 6 No No 130/84 114 164 4.39 0.87 0.77 126.44 60 1 
8 Maheswari 1019/02 50 Female Hindu 24.24 11 13 No No 140/78 126 178 5.25 1.16 0.82 228.96 60 1 
9 Palani 13152123 61 Male Hindu 24.16 12 11 No No 140/84 132 184 5.2 1.12 0.92 234.85 60 1 
10 Thangarajan 1232/11 72 Male Hindu 25.71 9 6 Yes Yes 130/86 110 174 4.3 1.11 1.01 178.91 60 1 
11 Vasudevan 703/10 52 Male Hindu 25.28 15 13 Yes Yes 136/94 118 176 3.1 1.59 1.78 237.09 89 1 
12 Saraswathi 2393/13 60 Female Hindu 25.89 11 11 No No 130/80 128 186 3.3 1.73 1.06 183.93 64 1 
13 Sankar 208/03 45 Male Hindu 25.65 10 6 Yes Yes 140/90 130 194 4.76 0.98 0.94 184.24 65 1 
14 Amsa 767/10 60 Female Hindu 28.67 15 12 No No 130/84 114 202 4.33 1.15 0.6 135.72 60 1 
15 Rajam 1171/08 56 Female Hindu 26.37 6 6 No No 140/78 108 208 4.97 1.57 0.64 243.68 74 1 
16 Subathra 1559/06 51 Female Christian 26.22 13 13 No No 134/70 76 146 5.2 1.5 0.9 296.7 60 1 
17 Ranjitham 1365/08 50 Female Hindu 23.44 6 6 No No 128/92 114 172 4.7 1.1 0.7 164.03 67 1 
18 Nirmala 972/04 45 Female Christian 24.03 6 6 No No 130/92 120 160 4.49 1.14 0.92 184.51 67 1 
19 mani 3827/06 45 Male Hindu 24.38 7 6 No Yes 128/88 130 170 3.97 1.02 1.13 159.72 71 No 
20 Subramaniyan 424/12 73 Male Hindu 24.16 6 10 No No 130/90 126 172 4.9 1.11 0.9 207.18 72 No 
21 Muthukumar 2481/13 58 Male Hindu 25.82 6 6 No No 140/90 130 200 4.14 1.3 1.1 203.52 67 No 
22 Varadhamma 937/10 65 Female Hindu 27.99 7 7 No No 130/80 110 160 4.9 1.3 0.9 236.27 65 No 
23 Bangarammal 1484/13 66 Female Hindu 28.76 7 10 No No 120/80 106 156 4.8 1.1 1 213.03 67 1 
24 Kuyilammal 844/08 60 Female Hindu 27.27 6 6 No No 130/80 110 170 3.9 1.3 1.1 184.76 65 1 
  
25 Vanaja 2373/08 55 Female Hindu 22.76 7 7 No No 120/80 120 180 4.1 1.5 1 213.72 63 1 
26 Vijaya 910/08 62 Female Hindu 25.72 11 15 No No 140/90 118 168 4 0.8 0.8 102.48 65 1 
27 K.R.Ravi 817/12 51 Male Hindu 25.82 10 10 No Yes 130/90 130 190 4.5 0.8 0.7 116.27 62 1 
28 Ayyappan 274/07 64 Male Hindu 24.98 6 10 Yes No 120/80 120 170 5 1.2 1.1 260.98 60 1 
29 Vijaya 907/10 43 Female Hindu 26.56 7 7 No No 130/90 110 170 3.9 0.9 0.6 88.47 68 No 
30 Mohan 1519/07 54 Male Hindu 23.81 6 6 No Yes 140/90 120 170 4.6 1.1 0.9 184.17 69 No 
31 Venkatesan 2447/09 50 Male Hindu 24.22 20 16 No No 120/80 117 178 4.8 0.9 0.9 170.38 70 1 
32 Kasi 2520/08 60 Male Hindu 26.85 6 7 No No 140/80 120 170 4.9 1.25 1.17 271.96 65 No 
33 Emely 2738/08 60 Female Christian 25.56 6 10 No No 120/80 118 188 5 1.2 1 244.58 67 1 
34 Vengammal 1582/07 65 Female Hindu 23.53 6 6 No No 130/80 130 170 5.1 1.1 0.9 220.67 62 1 
35 Parvathy 383/09 55 Female Hindu 23.73 6 6 No No 130/80 108 178 4.6 1.04 0.9 176.09 67 No 
36 Krishnan 817/06 52 Male Hindu 23.88 6 6 No Yes 140/90 130 190 4.6 0.95 0.86 159.08 62 1 
37 mani 1342/03 65 Male Hindu 25.1 20 16 No No 120/80 120 170 4.9 1.2 0.78 202.73 67 1 
38 kanniyammal 822/08 50 Female Hindu 24.84 6 6 No No 120/80 130 170 4.2 1.15 0.82 153.63 63 1 
39 Thangam 4244/07 64 Female Hindu 23.05 8 10 No No 120/80 125 175 5.2 1.3 0.9 261.6 64 No 
40 Shantha 1510/06 57 Female Hindu 25.48 6 6 No No 140/80 126 190 4.3 1.4 0.9 202.71 60 1 
41 Pattu 652/10 70 Female Hindu 23.73 6 6 No No 130/90 108 178 5.2 1.32 1 282.44 65 No 
42 Suleka banu 1945/07 45 Female Hindu 22.76 6 6 No No 140/90 110 170 4.2 1 0.8 133.99 67 No 
43 Parimal Seivi 5315/06 53 Female Hindu 24.44 7 7 No No 130/80 120 190 4.7 1.23 1 224.55 63 1 
44 Angappan 1377/08 80 Male Hindu 25.56 6 6 No No 120/80 116 156 4.9 1.23 1.15 265.31 60 No 
45 Veerabathran 1313/10 45 Male Hindu 24.01 11 11 Yes No 140/90 128 190 3.9 1 0.8 117.31 67 1 
46 Pushparani 572/07 58 Female Hindu 27.41 12 15 No No 130/80 100 150 4.7 1.3 1 235.14 63 1 
47 Sethuraman 2044/13 56 Male Hindu 25.51 13 15 No No 120/80 96 160 5.1 1.3 1 269.88 63 1 
48 Lakshmipathy 2450/03 65 Male Hindu 25.46 11 12 No No 130/90 126 180 5.1 1 0.9 205.16 62 No 
49 Nagammal 211/06 75 Female Hindu 27.94 16 16 No No 130/90 116 140 5.23 1.23 1.1 286.99 60 1 
50 Thanikachalam 1322/68 68 Male Hindu 23.81 16 16 No No 120/80 108 132 4.5 1.5 0.9 233.28 63 No 
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1 Lakshmanan 231 43 Male Hindu 22.1 No No Yes No 120/80 100 136 4.6 0.7 0.6 98.76 60 No 
2 Saradha bai 232 57 Female Hindu 27.77 No No No No 130/80 90 121 4.1 0.7 0.65 83.08 66 No 
3 Thilagavathi 201 51 Female Hindu 26.84 No No No No 130/80 108 123 3.8 0.7 0.72 77.26 70 No 
4 Sundari devi 220 37 Female Hindu 25.08 No No No No 110/80 110 132 3.9 0.75 0.65 79.54 76 No 
5 Sampath 152 50 Male Hindu 26.84 No No Yes Yes 120/80 104 134 4.6 0.81 0.61 112.06 64 No 
6 Jothi 190 50 Female Hindu 21.47 No No No No 100/70 86 112 3.7 0.78 0.71 79.11 67 No 
7 vengaiah 169 63 Male Hindu 23.29 No No No No 120/80 98 122 3.6 0.72 0.61 62.49 72 No 
8 Thanigaimalai 199 49 Male Hindu 28.74 No No Yes No 130/80 78 123 5 0.7 0.6 116.45 68 1 
9 Usha 218 53 Female Hindu 24.69 No No No No 120/80 90 134 4.5 0.6 0.56 80.2 69 No 
10 Janaki 209 52 Female Hindu 28.23 No No No No 110/70 86 138 5.2 1 0.7 181.82 70 1 
11 Kothai 202 37 Female Hindu 28.54 No No No No 120/80 120 142 4.2 0.7 0.6 82.38 65 No 
12 David selvaraj 208 44 Male Christian 24.31 No No Yes No 120/80 116 133 4.4 0.8 0.71 112.49 64 No 
13 Devika 240 38 Female Hindu 25.39 No No No No 110/70 100 120 4.2 0.71 0.65 88.1 68 No 
14 Surgunavathi 187 46 Female Hindu 24.22 No No No No 120/80 78 134 4.2 0.7 0.6 82.38 72 No 
15 Ashok kumar 223 56 Male Hindu 24.61 No No No No 110/80 84 126 5.1 1.1 0.9 220.67 74 1 
16 Radha 170 37 Female Hindu 24.46 No No No No 110/70 98 128 4.1 0.8 0.6 87.75 68 No 
17 Kalavathi 141 49 Female Hindu 24.24 No No No No 120/80 90 108 3.9 0.8 0.7 88.47 69 No 
18 Jayanthi 140 49 Female Hindu 24.03 No No No No 120/70 84 110 3.8 0.72 0.62 70.56 70 No 
19 Baskaran 139 53 Male Hindu 23.8 No No No No 130/80 78 112 4.2 0.9 0.6 101.95 72 No 
20 Ranganathan 147 54 Male Hindu 24.61 No No No No 130/80 90 124 4.6 0.8 0.76 128.27 76 No 
21 Nandhini 146 47 Female Hindu 23.83 No No No No 120/80 124 140 4.1 0.8 0.75 102.3 74 No 
22 Esther 149 48 Female Christian 23.63 No No No No 130/80 108 128 4.2 0.8 0.68 99.93 75 No 
23 Mahesh 157 41 Male Hindu 23.53 No No No No 110/80 120 138 4.3 0.9 0.6 106.63 79 No 
24 Lakshmaiah 164 50 Male Hindu 25 No No No Yes 130/86 112 136 4.7 0.8 0.6 114.48 78 No 
25 Ramamoorthy 165 48 Male Hindu 23.62 No No No Yes 110/78 114 132 4.5 0.8 0.8 127.69 77 No 
26 Gopal 161 49 Male Hindu 25.64 No No No No 128/88 118 134 4.9 0.85 0.75 149.66 65 No 
27 Muthukumar 168 50 Male Hindu 24.61 No No No No 120/80 108 124 4.7 0.82 0.72 131.11 67 No 
28 Raj 171 50 Male Hindu 26.56 No No No Yes 130/80 92 114 4.1 0.8 0.66 93.48 67 No 
29 Janaki 162 57 Female Hindu 24.24 No No No No 130/80 86 112 3.6 0.76 0.7 84.86 68 No 
30 Meena 160 37 Female Hindu 22.6 No No No No 110/80 96 128 4.4 0.8 0.78 120.21 66 No 
31 Seetharam 192 58 Male Hindu 25.39 No No No No 120/82 104 138 4.9 0.9 0.6 136.67 65 No 
32 Rajan 193 59 Male Hindu 27.18 No No No Yes 130/88 121 140 4.3 0.76 0.65 97.33 69 No 
33 Kasthuri 194 55 Female Hindu 23.63 No No No No 128/84 112 130 4.1 0.7 0.65 83.08 66 No 
34 Chandra 196 45 Female Hindu 24.65 No No No No 130/80 117 134 4.2 0.72 0.68 91.99 65 No 
35 Vasanthi 174 50 Female Hindu 26.22 No No No No 136/86 109 138 4 0.76 0.7 89.12 65 No 
36 Anbu 233 53 Female Hindu 23.44 No No No No 130/80 100 128 4.5 0.91 0.65 123.08 65 No 
37 Suseela 228 36 Female Hindu 22.6 No No No No 110/80 100 138 4 0.8 0.7 92.87 65 No 
38 Hemalatha 226 50 Female Hindu 24.34 No No No No 120/80 102 128 4.2 0.95 0.75 122.94 65 1 
39 Jayalakshmi 221 50 Female Hindu 25.39 No No No No 110/80 86 126 4.1 0.7 0.7 87.75 67 No 
40 Manohari 216 51 Female Hindu 24.46 No No Yes No 124/84 94 128 3.9 0.8 0.7 88.47 68 No 
41 Sundar 207 47 Male Hindu 25.3 No No No No 114/78 120 134 4.5 0.79 0.7 115.15 68 No 
42 Vijay Anand 213 41 Male Christian 24.38 No No No No 112/76 114 136 4.7 0.8 0.7 126.29 68 No 
43 Venkatesan 211 41 Male Hindu 24.45 No No No Yes 118/80 102 128 4.8 0.85 0.75 144.01 65 No 
44 Chinthamani 112 49 Female Hindu 23.71 No No No No 114/78 108 130 4.4 0.86 0.77 125.84 65 No 
45 Kusala 115 52 Female Hindu 23.42 No No No No 120/78 110 120 3.9 0.78 0.7 86.66 69 1 
46 Vasantha 116 56 Female Hindu 24.88 No No No No 134/84 90 130 4 0.8 0.6 83.6 66 No 
47 Tamilselvan 119 55 Male Hindu 25.07 No No No No 120/70 92 136 3.7 0.87 0.74 89.43 65 No 
48 Suresh 120 38 Male Hindu 26.29 No No Yes No 120/80 86 128 4.1 0.8 0.7 97.36 67 No 
49 Padmini 143 59 Female Hindu 24.69 No No No h 110/70 102 128 4 0.8 0.75 97.63 65 No 
50 Prabavathy 234 60 Female Hindu 26.91 No No No No 110/76 92 138 4.1 0.82 0.72 101.3 70 1 
 Abbreviations Used in MASTER CHART: 
HT                   - Hypertension 
DM                  - Diabetes Mellitus 
BMI                 - Body Mass Index 
LV mass          - Left Ventricular Mass 
IVST                - InterVentricular Septal Thickness 
PWT                - Posterior Wall Thickness 
LVID               - Left Ventricular Internal Diameter 
EF                    - Ejection Fraction 
DD                   - Diastolic Dysfunction 
FBS                  - Fasting Blood Sugar 
PPBS                - Post Prandial Blood Sugar 
FBS                  - Fasting Blood Sugar 
BP                    - Blood Pressure 
 
